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INTRODUCTION
A drug1 may be defined as  a  chemical  compound that  may be used on or
administered to help diagnose, treat, cure, mitigate, prevention, treatment of diseases
in human beings or  animals,  for altering any structure or function of  the body of
human beings or animals2.  
Regulatory definition: An article or substance that is 
1.  Recognized  by  the  US  Pharmacopoeia,  National  Formulary,  or  official
Homeopathic Pharmacopoeia, or supplement to any of the above 
2.  Intended  for  use  in  the  diagnosis,  cure,  mitigation,  treatment  or  prevention  of
disease in man or animals 
3. Intended to affect the structure or any function of the body of man or animals.
Substance abuse any medication; the word drug also carries a negative connotation–
implying abuse, addiction or illicit use.
Pharmaceutical  chemistry3-6 is  a  science that  makes use of general  laws of
chemistry  to  study  drugs  i.e.  their  preparation,  chemical  nature,  composition,
structure, influence on an organism, the methods of quality control and the conditions
of their storage etc. The family of drugs may be broadly classified as
1. Pharmacodynamic agents
2. Chemotherapeutic agents
Pharmacodynamic  agents7 refer  to  a  group  of  drugs  which  stimulates  or
depress various functions of the body so as to provide some relief to the body in case
of body abnormalities, without curing the disease.
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Chemotherapeutics agents are drugs, which are selectively more toxic to the
invading organisms without  causing harmful  effect  to  the  host.  Eg:  Antimalarials,
antibacterials, antifungal agents
Every country has legislations8 on bulk and their pharmaceutical formulations
that  sets  standard  and  obligatory  quality  indices  for  them.  These  regulations  are
presented in separate articles relating to individual drugs and are published in the
form  of  book  called  “Pharmacopoeia”  [e.g.  IP9,  BP10 and  Martindale  Extra
Pharmacopoeia11 (MEP)].
Analytical chemistry12-15 is the science to analyze morphologies, compositions,
and quantities of analytical targets. These analytical results have played critical roles
from the understanding of basic science to a variety of practical applications, such as
biomedical  applications,  environmental  monitoring,  quality  control  of  industrial
manufacturing, and forensic science.
An effort to develop a new method might involve the use of a tunable laser to
increase  the  specificity  and  sensitivity  of  a  spectrophotometric  method.  Many
methods, once developed, are kept purposely static so that data can be compared over
long periods of time. This is particularly true in industrial quality assurance (QA),
forensic and environmental applications. 
Types16,17
Traditionally, analytical chemistry has been split into two main types, 
qualitative and quantitative:
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There are main two types of chemical analysis. 
1. Qualitative (identification) 
2. Quantitative (estimation)
1.  Qualitative analysis is  performed to  establish  composition of  natural/synthetic
substances. These tests are performed to indicate whether the substance or compound
is present in the sample or not. Various qualitative tests are detection of evolved gas,
formation  of  precipitates,  limit  tests,  colour  change  reactions,  melting  point  and
boiling point test etc.
2. Quantitative analytical techniques are mainly used to quantify any compound or
substance  in  the  sample.  These  techniques  are  based  on  (a)  The  quantitative
performance of suitable chemical reaction   and either measuring the amount of reagent
added to complete the reaction or measuring the amount of reaction product obtained,
(b) The characteristics movement of a  substance through a defined medium under
controlled  conditions,  (c)  Electrical  measurement  and  (d)  Measurement  of  some
spectroscopic properties of the compound.
Pharmaceutical analysis  18-19   plays a very significant role in quality control of
pharmaceuticals through a rigid check on raw materials  used in  manufacturing of
formulations and on finished products.  It  comprises those procedures necessary to
determine  the  identity,  strength,  quality  and  purity  of  substances  of  therapeutic
importance.  The  use  of  analytical  sciences  in  the  discovery,  development  and
manufacture of pharmaceuticals is wide ranging. It  also plays an important role in
building up the quality products through in process quality control. Pharmaceutical
analysis is the application of principles of analytical chemistry to drug analysis. 
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Pharmaceutical analysis  20,21   deals not only with medicaments (drugs and their
formulations)  but  also  with  their  precursors  i.e.  with  the  raw materials  on  which
degree of  purity and quality of  medicament  depends.  The quality  22   of  the drug is
determined after establishing its authenticity by testing its purity and the quality of
pure substance in the drug and its formulations.
The  methods  of  estimation  of  drugs  are  divided  into  physical,  chemical,
physicochemical  and  biological  ones.  Physico-chemical  and  physical  methods  are
used  the  most.  Physicochemical  methods  23-25   are  used  to  study  the  physical
phenomenon that occurs as result of chemical reactions. Among the physicochemical
methods,  the  most  important  are  optical  (refractometry,  polarimetry  including
photocolourimetry  and  spectrophotometry  covering  UV-visible  and  IR  regions
nephelometry or turbidimetry) and chromatographic (column, paper, thin-layer  26  , gas
liquid  27,28  , HPLC  29-30  ) methods. The number of new drugs is constantly growing. This
requires  new methods for  controlling the quality.  Modern pharmaceutical  analysis
must need the following requirements.
1. The analysis should take a minimal time.
2. The accuracy of the analysis should meet the demands of Pharmacopoeia.
3. The analysis should be economical.
4. The selected method should be precise and selective.
5. These requirements are met by the Physico-chemical methods of analysis, a
merit of which is the universal  nature that can be employed for analyzing organic
compounds with a diverse structure. 
Types of Analysis 
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The factors which must be taken into account when selecting an appropriate
method of analysis are: 
(a) The nature of the information sought 
(b) The size of sample available and the proportion of the constituent to be determined
(c) The purpose for which the analytical data is required. 
Different types of chemical analysis may be classified as: 
(i) Proximate Analysis: 
The amount of each element in a sample is determined with no concern as to the
actual components present. 
(ii) Partial analysis: 
Deals with the determination of selected constituents in the sample.
(iii) Trace constituent analysis: 
A specialized form of partial analysis in which determination of specified components
present in very minute quantity.
(iv) Complete Analysis: 
When the proportion of each component of the sample is determined. 
Different Techniques of Analysis 
The main techniques are based upon: 
1.  The quantitative performance of suitable chemical reactions 
2.  Appropriate electrical measurements 
3.  Measurement of certain optical properties and 
4. Combination of optical and electrical measurement followed by quantitative
chemical reaction 
1. Methods Based on Chemical Analysis31-33: 
These methods are based on traditional method of analysis and may be divided as:
(i)  Titrimetry 
(ii)  Gravimetry 
(iii)  Volumetry 
(i) Titrimetric Analysis34:
In  this  technique  the  substance  to  be  determined  is  allowed  to  react  with  an
appropriate reagent added as a standard solution, and the volume of solution needed
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for  completion  on  reaction  is  determined.  Following  are  the  types  of  titrimetric
analysis. 
• Neutralization (acid-base) reactions 
• Complexometric titrations 
• Precipitation titrations 
• Oxidation-reduction titrations
• Non aqueous titrations
(ii) Gravimetric Analysis35:
In  this  technique  substance  under  determination  is  converted  into  an  insoluble
precipitate which is collected and weighed. In a special case of gravimetric analysis,
electrolysis of the substance is carried out and the material deposited on one of the
electrodes is weighed. This technique is called as electrogravimetry.
(iii) Volumetry Analysis:
It is concerned with measuring the volume of gas evolved or absorbed in a chemical
reaction.
 2. Electrical Methods of Analysis36,37:  These involve the measurement of current
voltage or resistance in relation to the concentration of a certain species in a solution.
These methods are of following types: 
a) Voltametry: 
It is the measurement of current at a microelectrode at a specified voltage. 
b) Coulometry: 
It  is  the measurement of  current  and time needed to  complete an electrochemical
reaction or to generate sufficient material to react completely with a specified reagent.
c) Conductometry:
 It is the measurement of electrical conductivity of a solution. The ionic reactions in
which there is a sudden change in conductance after completion of reaction, can act as
a basis of conductometric titration method. 
d) Potentiometry:
It is the measurement of the potential of an electrode in equilibrium with an ion to be
determined.
3. Optical Methods of Analysis38-40: 
The optical methods of analysis depend upon: 
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(a) Measurement  of  the  amount  of  radiant  energy  of  a  particular  wavelength
absorbed by the sample. 
(b) The emission of radiant energy and measurement of the amount of energy of a
particular wavelength emitted. 
The optical methods are basically of two types: 
• Absorption methods
• Emission methods
Absorption methods:
Absorption spectroscopy refers to spectroscopic techniques that measure the
absorption of  radiation,  as  a  function  of  frequency or  wavelength,  due  to  its
interaction with a sample. The sample absorbs energy, i.e., photons, from the radiating
field.  The  intensity  of  the  absorption  varies  as  a  function  of  frequency  and  this
variation is the absorption spectrum. Absorption spectroscopy is performed across the
electromagnetic  spectrum.  Absorption  spectroscopy  is  employed  as  an  analytical
chemistry tool to determine the presence of a particular substance in a sample and in
many cases, to quantify the amount of the substance present. 
Absorption methods are usually classified according to wavelength involved: 
i. Visible spectrophotometry 
ii. Ultraviolet spectrophotometry 
iii. Infrared spectrophotometry 
Visible spectrophotometry:
The  method  of  analysis  is  based  on  measuring  the  absorption  of
monochromatic light by coloured compounds in the visible path of the spectrum (370-
800nm). If the analytes are colourless, they are converted into coloured compounds by
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reaction with a suitable chromogenic reagent. In this case, the majority of coloured
compounds are complexes or complex ligands. The later must be stable and have a
constant composition and high colour intensity. The photometric methods of analysis
are based on the Bouger-Lamberts-Beer’s Law, which establishes that absorbance by a
solution is directly proportional to the concentration of the analyte. The fundamental
principle of operation of spectrophotometer covering visible region consists in that
light  of  definite  interval  of  wavelength  passes  through  the  radiant  energy  into
electrical energy measured by a galvanometer.
The absorption of light by analytes is due to the presence of chromophores in
their  molecules,  which  are  specific  portions  of  molecules  that  can  absorb  radiant
energy in the UV or visible region. They include unsaturated functional groups. Every
functional group in a molecule of a substance is characterized by the absorption of
light  in  a  definite  region  of  the  spectrum  and  this  property  is  used  for  the
identification  and  quantification  of  a  substance  in  a  drug  (bulk  sample  or
formulation).  In  addition  to  chromophores,  a  molecule  may contain  one  or  more
saturated functional  groups that  themselves do not absorb in the uv/visible region
being scanned, but can effect the behaviour of the chromophore that are conjugated
with these groups are called auxochrome (e.g. SH, NO2, OH), which usually cause
absorption  by  a  chromophore  at  higher  wavelength  and  at  a  longer  value  of  the
absorptivity than found for the given chromophores itself.
Absorption spectrum:
The absorption spectrum is a graphical representation of the amount of light
absorbed by a substance at definite wavelengths. To plot absorption curve, the value
of the wavelength (λ) are laid off along the axis of abscissas and the values of the
absorbance along the axis of ordinates. A characteristic of an absorption spectrum is a
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position  of  the  peaks  (maxima)  of  light  absorption,  which  is  determined  by  the
absorptivity at definite wavelengths.
Beer’s law plot
A standard specimen of the analyte is taken and the solutions of it with known
concentrations are prepared. The absorbance of all the solutions are measured at a
definite wavelength (λmax) and the calibration curve is plotted by laying off the known
concentrations along the axis abscissas and the absorbances corresponding to them
along the axis ordinates.  The calibration curve is  used to  determine  the unknown
concentration of the analyte in its solutions.
A feature  of  organic  drugs  is  the  presence  of  functional  groups  in  their
molecules i.e., reactive atoms or groups of atoms determined by chemical reactions.
Functional  groups determine the way of analysing organic drugs because they are
responsible for the properties of substance and determine the identification reactions
and the methods of quantitative determination of drugs. Knowing the reactions for
detecting functional groups, one can easily and conscientiously analyze any organic
drug  with  a  complicated  structure.  There  are  several  drug  molecules,  which  are
polyfunctional in nature, i.e., simultaneously contain two or more functional groups42-
45
.
Functional groups in drugs can be classified into three categories.
1. Functional groups imparting an acidic nature to a substance.
2. Functional groups imparting basic properties to a substance.
3. Functional group which exhibit neither acidic nor basic properties.
Emission methods:
In emission method sample is subjected to heat or electrical treatment so that
the atoms are raised to excited states causing them to emit-energy; and the intensity of
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this  emitted  energy  is  measured.  The  emission  spectroscopy  includes  flame
photometry and fluorimetry as common excitation techniques. 
In emission spectroscopy the sample is subjected to an electric arc or spark plasma
and the light  emitted is  examined.  Flame photometry involves  the solution of  the
sample, injected into a flame while in fluorimetry a suitable substance in solution is
excited by irradiating with visible or ultraviolet radiation. 
CHROMATOGRAPHY46-49
Chromatography is an analytical method that finds wide application for the
separation,  identification  and  determination  of  chemical  compounds  in  complex
mixtures. This technique is based on the separation of components in a mixture (the
solute) due to the difference in migration rates of the components through a stationary
phase by a gaseous or liquid mobile phase. 
Types of chromatography50-52:
Chromatography
Gas chromatography  Gel chromatography             Liquid chromatography
Gas-solid             Gas- liquid          Filtration      Permeation   Ion-Interaction              Ion-Exclusion
  Ion-Exchange                Ion-chrom.
  Adsorption                   Partition chrom.
                   TLC         Reverse-Phase               
                                                                                                                                            Paper chrom. 
Some of the different types of chromatography are discussed below:
Gas Chromatography (GC) 53-55
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Gas  chromatography  is  a chromatographic technique  that  can  be  used
to separate organic compounds that are volatile. A gas chromatography consists of a
flowing mobile phase, an injection port, a separation column containing the stationary
phase, a detector, and a data recording system. The organic compounds are separated
due to differences in their partitioning behaviour between the mobile gas phase and
the stationary phase in the column.
Exclusion or Gel Permeation Chromatography:
This technique separates analytes according to their molecular size and shape.
Resins  for  exclusion  chromatography  include  silica  or  polymer  particles,  which
contain  a  network  of  uniform pores  into  which  the  solute  and  solvent  molecules
diffuse. As a sample moves through the column the analytes are separated as the lower
molecular weight species are held back due to permeation of the particle pore whereas
the higher molecular weight species are larger than the average size of the pore and
are excluded. Thus the larger species move through the column faster. 
Liquid chromatography
Liquid chromatography (LC) is a separation technique in which the mobile
phase is a liquid. Liquid chromatography can be carried out either in a column or a
plane.  Present  day  liquid  chromatography  generally  utilizes  very  small  packing
particles  and  a  relatively  high  pressure  is  referred  to  as  high  performance  liquid
chromatography (HPLC).
High-performance liquid chromatography (HPLC) 56,57
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The typical HPLC separation is based on the selective distribution of analytes
between a liquid mobile phase and an immiscible stationary phase. The sample is first
introduced by means of an injection port into the mobile phase stream that is delivered
by a high-pressure pump. Next, the components of this sample mixture are separated
on the  column,  a  process  monitored  with  a  flow-through  detector  as  the  isolated
components emerge from the column. 
GENERAL METHODOLOGY FOR THE ANALYTICAL METHOD
DEVELOPMENT
Analytical method development 58,59:
• Analytical  method  development  plays  important  role  in  the  discovery,
development and manufacturing of pharmaceuticals.
• The  official  analytical  methods  that  result  from these  processes  are  used  by
quality  control  laboratories  to  ensure  the  identity,  purity,  potency  and
performance of drug products.
Goals: 
• To improve the degree of accuracy and precision.
• For better recovery of drugs.
• Improvement of sensitivity and/or specificity.
• Simpler and easier method.
• Reduce the cost (cost of operation and running cost of HPLC are high) etc.
Development of a method:
In  developing  a  quantitative  method  for  determining  an  unknown
concentration of a given substance by absorption spectrophotometry, the first step will
be  the  selection  of  analytical  wavelength  can  be  chosen  either  from literature  or
experimentally by means of a scanning spectrum in the UV-Visible region. In order to
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enhance the sensitivity of the method and signal to noise ratio,  the wavelength of
maximum  absorbance  is  chosen  as  analytical  wavelength.  After  selection  of  the
wavelength, the colour developing reagent and the absorbing product must be stable
for a considerable period of time. Always the preparation of standards and unknown
should be on a definite time schedule. 
Optimization of analytical method60:
The bases of the spectrophotometric methods, in the present investigation are
(a) oxidative coupling (b) oxidation followed by complex formation (c) diazotization
and  coupling   (d)  complex  formation.  In  each  type  of  reaction,  the  yield  of  the
coloured  species  whose  absorbance  is  measured  and  thus  the  sensitivity  of  the
method, rate of colour formation and stability are affected by the concentration of the
reagent  in  the solution.  The nature  of  the solvent,  the temperature,  the pH of  the
medium,  order  of  addition  of  reactants  and  waiting  periods  also affect  the  above
parameters.  For  simple  systems  having  no  interaction  between  variables,  the  one
variable  at  time  (OVAT)  strategy  appears  to  be  simple,  efficient  and  effective  to
establish the optimum conditions. The OVAT approach requires all variable but one to
be held constant while a univariate search is carried out on the variable of interest. 
Calibration:
Calibration  is  one  of  the  most  important  steps  in  drug  analysis.  A good
precision and accuracy can only be obtained when good calibration procedure is used.
In  spectrophotometric  methods the concentration of a  sample cannot  be measured
directly,  but  is  determined  using  another  physical  measuring  quantity,  “Y”
(absorbance of a solution). An unambiguous empirical or theoretical relationship can
be shown between this quantity and concentration of the analyte. 
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The calibration function can be obtained by fitting an adequate mathematical
through the  experimental  data.  The most  convenient  calibration function  is  linear,
goes through the origin and is applicable over a wide dynamic range. In  practice,
however many deviations from this ideal calibration line may occur. For the majority
of analytical techniques the analyst uses the calibration equation.
                                                          Y= a + bX
Where a is intercept and b is slope.
In  calibration  univariate  regression  is  applied,  which  means  that  all
observations are dependent upon a single variable “X”.
The method of least squares61
Least squares regression analysis is used to describe the relationship between
signal and concentration. All models describe the relationship between response (Y)
and concentration (X) can be represented by general function.
                                             Y= f(X, a1, b1............bm)
            Where a1, b1............bm are the parameters of the function
             We adopt  the convention that  ‘X’ values  relate  to  the  controlled or
independent variable and the ‘Y’ values to the dependent variable. This means that ‘X’
value has no error. On the condition that errors made in preparing the standards are
significantly  smaller  than  the  measuring  errors  this  assumption  is  realistic  in
calibration  problems.  The  values  of  unknown  parameter  a1,  b1............bm  must  be
estimated in such a way that the model fits the experimental data points as far as
possible.
             The true relationship between X and Y is considered to be given by a straight
line. The relationship between each observation pair (Xi, Yi) can be represented as 
Yi=α + βXi + ei
                                                                14
             The signal Yi is composed of a deterministic component predicted by linear
model and a random component ei. One must now find the estimates ‘a’ and ‘b’ of the
true values and α and β which are constants. This is done by calculating values ‘a’ and
‘b’ for which ∑ei2 is minimal. The component ei represents the difference between the
observed Yi values by the model. The ei  are called the residuals, ‘a’ and ‘b’ are the
intercept and slope respectively. The equation given for slope and intercept of the line
are as follows.
                                                                                      n∑iXi Yi -∑iXi . ∑iYi  
                                                       Slope (b) =     
                                                                                 n∑iXi2 – [∑iXi]2
                                                                             ∑iYi∑iXi2-∑iXi . ∑iXi Yi
                                                   Intercept (a) =
                                                                         n∑iXi2 – [∑iXi]2
Correlation coefficient (r)                             
                The correlation coefficient r (x, y) is more useful to express the relationship
of the chosen scales. To obtain a correlation, the covariance is divided by the product
of the standard deviation of x and y.
                                  
r=
[∑
i=1
n
(X iX )(Y iY )]
(n1 )
[∑
i=1
n
(X iX )
2∑
i=1
n
(Y iY )
2]
(n1 )2
Where   X ,Y  are the arithmetic means of X and Y respectively.
Selectivity of the method
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              The determination of an analyte may be disturbed by matrix and interference
effect.  Some  of  the  excipients,  incipient  and  additives  present  in  pharmaceutical
formulations may sometimes interfere in the assay of the drug and in such instances
appropriate  separation  procedure  is  to  be  adopted  initially.  The selectivity  of  the
method ascertained by studying the effect of a wide range of excipients and other
additives  usually  present  in  the  pharmaceutical  formulation  on  the  determinations
under optimum conditions.
                 In the initial interference studies, a fixed concentration of the drug is
determined several times by the optimum procedure in the presence of suitable (1 to
100 fold) molar excess of foreign compounds under investigation and its effect on
absorbance of solution is noticed. The foreign compound is considered to be non-
interfering if at these concentrations, it constantly produces an error less than 3% in
the absorbance produced in the pure sample solution.
Linearity and sensitivity of the method
              Knowledge of the sensitivity of the colour is important and the following
terms are commonly employed for expressing the sensitivity. According to the Beer’s
law
                                                          Intensity of incident radiation
                                            A= log                                                 =   ε. C. t
                                                          Intensity of transmitted light
              
              The absorbance (A) is proportional to the concentration (C) of absorbing
species if absorptivity (ε) and thickness of the medium (t) are constant. When ‘C’ is in
moles per liter, the constant ε is called the molar absorptivity. Beer’s law limits and
εmax values are expressed as μg/ml and mole-1cm -1 respectively
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              Sandell’s sensitivity62 refers to the number of μg of the drug determined,
converted to the colored product, which in a column solution of cross section 1cm2
shows an absorbance 0.001 (expressed as μg cm-2). 
Ringbom’s plot63
                The relative concentration error depends inversely upon the product
absorbance  and  transmittance.  The relative  error  increases  at  the  extremes  of  the
transmittance  (T) scale.  The slope of  plot  ‘C’ versus  T, i.e.  Ringbom’s plot  gives
relative coefficient (i.e. plot of log C α T). The main limitation of the ringbom’s  plot
is  that  it  provides  no  information  concerning  the  concentration  range  of  good
precision unless it is combined with ∆T versus T relation. The above expression is
valid whether or not Beer’s law is valid.
Precision and accuracy
                 The purpose of carrying out a determination is to obtain valid estimation of
a  true  value,  when  one  considers  the  criteria  according  to  which  an  analytical
procedure is selected, precision and accuracy are usually the first to come to mind.
Precision and accuracy together determine the error of an individual determination.
They are among the most important criteria for judging analytical procedures by their
results.
Precision
               Precision refers to the reproducibility of measurement with in a set that is to
the scatter or dispersions of a set about its central value. The term ‘set’ is defined as
referring to a number (n) of independent replicate measurements of some property.
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One of the most common statistical terms employed is the standard deviation of a
population observation. Standard deviation is the square root of the sum of squares of
deviations of individual results from the mean, divided by one less than the number of
result in the set. The standard deviation ‘S’ is given by
S=√ 1n1∑i=1
n
(X iX )
2
                Standard deviation has the same units as the property being measured.
The square of the standard deviation is  called the variance (S2).  Relative standard
deviation expressed as a fraction of the mean. It is sometimes multiplied by 100 and
expressed as a percent relative standard deviation (coefficient of variance). This is
more accurate measure of the precision.
                                                   %CV = S x 100 / X
Where S= standard deviation
          X = Mean
   % CV = coefficient of variation
Accuracy
               The test for accuracy of the method is carried out by taking varying amounts
of  the  constituents  and  proceeding  according  to  the  specified  instructions.  The
difference between the means of an adequate number of results and the amount of
constituent actually present, usually expressed as part per hundred (%) i.e. % error.
              The constituent in question will usually have to be determined in the
presence of other substances and it will therefore be necessary to know the effect of
these upon the determination. This will require testing the influence of a large number
of  portable compounds in  the chosen samples  each in  varying amounts.  In  a few
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instances,  the accuracy of the method is controlled by separations (usually solvent
extraction or chromatography technique) involved.
Comparative method
              In the analysis of pharmaceutical formulations or laboratory prepared
samples  of  desired  composition,  the  content  of  the  constituent  sought  has  been
determined by two or more ‘accurate’ methods of essentially different character can
usually be accepted as indicating the absence of appreciable determination error. The
general procedure for the assay of pharmaceutical formulations either in proposed or
reference  methods  comprises  of  various  operations  which  include  sampling,
preparation of solution, separation of interfering ingredients if any and the method for
quantitative assay.
Recovery experiments (standard addition method)
                   A known amount of the constituent being determined is added to the
sample which is analyzed for the total amount of constituent present. The difference
between the analytical  results  for  samples with and without the added constituent
gives the recovery of the amount of added constituent. If recovery is satisfactory our
confidence in the accuracy of the procedure will be enhanced. 
                  Usually,  recovery studies  are  performed  while  proceeding  for
pharmaceutical  formulations;  known amounts  of an analyte are spiked at  different
levels into a sample matrix, which was already analyzed. The concentration of the
analyte in the original sample may then be determined mathematically.
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                                  % Recovery = [N (∑ XY )∑ X .∑YN (∑ X 2)(∑ X )2 ]×100
X= amount of standard drug
Y= amount of drug found by the proposed method
N= Number of observations
ANALYTICAL METHOD VALIDATION AS PER ICH GUIDELINES64-67
Method  validation  is  the  process  to  confirm  that  the  analytical  procedure
employed  for  a  specific  test  is  suitable  for  its  intended  use.  Methods  need  to  be
validated or revalidated.
• Before their introduction into routine use
• Whenever the conditions change for which the method has been validated,
e.g., instrument with different characteristics
• Whenever the method is changed, and the change is outside the original scope
of the method.
Method validation is completed to ensure that an analytical methodology is
accurate, specific, reproducible and rugged over the specified range that an analyte
will be analyzed. Method validation provides an assurance of reliability during normal
use, and is sometime referred to as "the process of providing documented evidence
that the method does what it is intended to do." Regulated laboratories must perform
method validation in order to be in compliance with FDA regulations.
For method validation, these specifications are listed in USP Chapter <1225>,
and can be referred to as the "Eight Steps of Method Validation," These terms are
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referred to as  "analytical  performance parameters",  or  sometimes as "analytical
figures of merit." Most of these terms are familiar and are used daily in the laboratory.
In response to this situation, one of the first harmonization projects taken up by the
ICH was the development of a guideline on the "Validation of Analytical Methods:
Definitions and Terminology68." 
METHOD VALIDATION
The developed methods were validated by following steps
• Accuracy
• Precision
• Specificity
• Limit of quantitation
• Limit of detection
• Linearity and range
• Ruggedness and
• Robustness
Accuracy:
It  is defined as closeness of agreement between the actual (true) value and
mean analytical value obtained by applying a test method number of times. Accuracy
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of an analytical method is determined by systematic error involved. The accuracy is
acceptable if the difference between the true value and mean measured value does not
exceed the RSD values obtained for repeatability of the method. To determine the
accuracy of the proposed method, different levels of drug concentrations three serial
dilutions were prepared from independent stock solutions and analyzed. Accuracy was
assessed  as  the  percentage  relative  error  and  mean  %  recovery.  To  provide  an
additional support to the accuracy of the developed assay method, a standard addition
method was  employed,  which involved the addition of  different  concentrations  of
pure drug to a known preanalyzed formulation sample and the total concentration was
determined.
The % recovery of the added pure drug was calculated as
 % recovery = [(Ct–Cs)/Ca] x 100,
 Where,
Ct is the total drug concentration measured after standard addition;
 Cs drug concentration in the formulation sample; 
Ca, drug concentration added to formulation.
Precision:
The  precision  of  an  analytical  method  is  the  degree  of  agreement  among
individual test results when the method is applied repeatedly to multiple sampling of
homogenous sample.  Precision is  the measure of the degree of repeatability of an
analytical method under normal operation and is normally expressed as the percent
relative standard deviation for a statistically significant number of samples. According
to  the  ICH, precision  should be performed at  three  different  levels:  repeatability,
intermediate precision, and reproducibility.  The precision of an analytical method is
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determined by assaying a sufficient number of aliquots of a homogenous sample to be
able to calculate statistically valid estimates of standard deviation or relative standard
deviation. The ICH documents recommended that the repeatability should be assessed
using  a  minimum  of  nine  determinations  covering  the  procedure  (i.e.  three
concentration and three replicates  of  each concentrations  using a  minimum of six
determinations at 100% of the test concentrations).
In the case of instrument precision, six replicates of the standard solution are
made for the test performance of the chromatographic instrument.
In  the  case  of  method  precision,  six  replicates  from  the  same  batch  are
analyzed for the assay and dissolution parameters and observing the amount of scatter
in  the  results.  An  example  of  precision  criteria  of  an  assay  method  is  that  the
instrument precision RSD should not be more than 2.0%.
Repeatability is the results of the method operating over a short time interval under
the same conditions (inter-assay precision). It should be determined from a minimum
of nine determinations covering the specified range of the procedure (for example,
three levels, three repetitions each) or from a minimum of six determinations at 100%
of the test or target concentration.
Intermediate precision is the results from within lab variations due to random events
such as different days, analysts, equipment, etc. In determining intermediate precision,
experimental design should be employed so that the effects (if any) of the individual
variables can be monitored.
Reproducibility refers to the results of collaborative studies between laboratories.
                                                                23
Documentation in support of precision studies should include the standard deviation,
relative standard deviation, coefficient of variation, and the confidence interval.
Specificity: 
It is the ability of an analytical method to assess unequivocally the analyte of
interest in the presence of components that may be expected to be present, such as
impurities,  degradation  products  and  matrix  components.  In  case  of  the  assay,
demonstration of specificity requires that the procedure is unaffected by the presence
of  impurities  or  excipients.  In  practice,  this  can  be  done  by  spiking  the  drug
substances  or  product  with  appropriate  levels  of  impurities  or  excipients  and
demonstrating  that  the  assay  is  unaffected  by  the  presence  of  these  extraneous
materials. If the degradation product impurity standards are unavailable, specificity
may be demonstrated by comparing the test results of samples containing impurities
or degradation products to a second well-characterized procedure. These comparisons
should  include  samples  stored  under  relevant  stress  conditions  (e.g.  light,  heat
humidity, acid/base hydrolysis, oxidation, etc.).
Limit of Detection:
The limit  of  detection (LOD) is  defined as  the  lowest  concentration of  an
analyte in a sample that can be detected, not quantitated. It is a limit test that specifies
whether or not an analyte is above or below a certain value. It  is expressed as the
concentration at  a  specified signal-to-noise ratio,  usually two or  three-to-one.  The
ICH  has  recognized  the  signal-to-noise  ratio  convention,  but  also  lists  two  other
options  to  determine  LOD:  visual  non-instrumental  methods  and  a  means  of
calculating  the  LOD.  Visual  non-instrumental  methods  may  include  LOD’s
determined  by techniques  such  as  thin  layer  chromatography (TLC)  or  titrations.
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LOD’s may also be calculated based on the standard deviation of the response (SD)
and the slope of the calibration curve (S) at levels approximating the LOD according
to the formula:  LOD = 3.3(SD/S).  The standard deviation of  the response can be
determined based on the standard deviation of the blank, on the residual  standard
deviation of the regression line, or the standard deviation of y-intercepts of regression
lines. The method used to determine LOD should be documented and supported and
an appropriate number of samples should be analyzed at the limit to validate the level.
Limit of Quantitation:
The Limit of Quantitation (LOQ) is defined as the lowest concentration of an
analyte in a sample that can be determined with acceptable precision and accuracy
under the stated operational conditions of the method. Like LOD, LOQ is expressed
as  the  concentration,  with  the  precision  and  accuracy  of  the  measurement  also
reported. Sometimes a signal-to-noise ratio of ten-to-one is used to determine LOQ.
This signal-to-noise ratio is a good rule of thumb, but it should be remembered that
the  determination  of  LOQ  is  a  compromise  between  the  concentration  and  the
required precision and accuracy. That is, as the LOQ concentration level decreases,
the precision increases. If better precision is required, a higher concentration must be
reported for  LOQ. The ICH has  recognized the ten-to-one signal-to-noise ratio as
typical, and also, like LOD, lists the same two additional options that can be used to
determine  LOQ,  visual  non-instrumental  methods  and  a  means  of  calculating  the
LOQ. The calculation method is based on the standard deviation of the response (SD)
and the slope of the calibration curve (S) according to the formula: LOQ = 10(SD/S). 
Linearity and Range:
Linearity is  the  ability of  the method to  elicit  test  results  that  are  directly
proportional  to  analyte  concentration  within  a  given  range.  Linearity  is  generally
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reported as  the variance  of  the  slope of  the regression line.  Range is  the interval
between the upper and lower levels of analyte (inclusive) that have been demonstrated
to be determined with precision, accuracy and linearity using the method as written.
The range is normally expressed in the same units as the test results obtained by the
method ICH25 recommended that, for the establishment of linearity, a minimum of
five concentrations. For assay of a drug substance or a finished product 80-120% of
the test concentration should be taken. For an impurity test, the minimum range is
from the reporting level of each impurity, to 120% of the specification. (For toxic or
more potent impurities, the range should be commensurate with the controlled level.)
Acceptability of the linearity data is often judged by examining the correlation
co-efficient  and  y-intercept  of  the  linear  regression  line  for  the  response  versus
concentration plot. The correlation coefficient of >0.999 is generally considered as
evidence of acceptable fit of the data to the regression line. The y-intercept should be
less than a few percent of the response obtained for the analyte at to target level.
Ruggedness:
Ruggedness,  according to  the  USP,  is  the  degree  of  reproducibility  of  the
results obtained under a variety of conditions, expressed as %RSD. The ruggedness of
an analytical method is the degree of reproducibility of test results obtained by the
analysis  of  the  same  samples  under  a  variety  of  conditions  such  as  different
laboratories,  different  analysts,  different  instruments,  different  lots  of  reagents,
different elapsed assay times, different assay temperatures, different days, etc.
Robustness:
Robustness  is  the  capacity  of  a  method  to  remain  unaffected  by  small
deliberate variations in method parameters. The robustness of a method is evaluated
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by  varying  method  parameters  such  as  percent  organic,  pH,  ionic  strength,
temperature, etc., and determining the effect (if any) on the results of the method. As
documented  in  the  ICH  guidelines,  robustness  should  be  considered  early  in  the
development  of  a  method.  In  addition,  if  the  results  of  a  method  or  other
measurements are susceptible to variations in method parameters, these parameters
should be adequately controlled and a precautionary statement included in the method
documentation.
The robustness of the methods was determined by performing the assay of the
triplicate by deliberately alternating parameters and that the results are not influenced
by different changes in the above parameters
   Change in column temperature ± 50C
   Change in flow rate ± 10%.
   Change in organic phase ± 2%.
   Change in pH ± 0.2.
            The system suitability and the precision of the assay were evaluated for the
respective condition. The robustness of an analytical procedure is the measure of its
capability  to  remain  unaffected  by  small,  but  deliberate  variation  in  method
parameters and providers an indication of its reliability during normal usage.
CHROMOGENIC REAGENTS USED IN THE PRESENT INVESTIGATION
Functional groups present in organic drugs determine the way of analysing
them because they are responsible for the properties of substances and determine the
identification reactions and the methods of quantitative determination of drugs. In the
present investigation, few visible spectrophotometric methods have been developed
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for  Lamotrigine  and  Levetiracetam  for  developing  colour  in  each  case  with,
appropriate reagent.
Generally  different  types  of  chemical  reactions  like  oxidative  coupling
(MBTH,  Gibb’s  reagent.  2,  4-DNP),  oxidation  followed  by  complex  formation
(potassium  ferricyanide),  complex  formation  (p-CA),  diazotization  and  coupling
(BMR) are used in developing visible spectrophotometric methods.
Reagents used:
• 2, 6-Dichloroquinone-4-chloroimide (Gibb’s),
• 3-methyl-2-benzthiazolinone hydrochloride (MBTH),
• 2, 4-Dinitrophenyl hydrazine (2, 4-DNP),
• Parachloranilic acid (p-CA)
• N-(1-napthyl) ethylene diamine hydrochloride (BMR)
• Potassium ferricyanide
2, 6 Dichloroquinone chlorimide69,70
2,  6  Dichloroquinone  chlorimide  is  also  called  as  Gibb’s  reagent.  Gibb’s
reagent  mainly  reacts  with  phenols,  primary  amines,  secondary  amines,  aliphatic
amines. For the present study the reagent was prepared in methanol.
3-Methyl 2-benzathiozolinone hydrazone71,72
 MBTH is synthesized by Besthron. MBTH reagent can react with carbonyl
compounds  and  compounds  containing  amine  group.  It  also  forms  a  strongly
electrophillic diazonium salt when acted upon by an oxidizing agent. Ferric chloride
has been mostly used as the oxidizing agent for the determination of amines. For the
present study the reagent was prepared in distilled water.
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2, 4-Dinitrophenyl hydrazine73.74
2,  4-Dinitrophenyl  hydrazine  reagent  is  also  called  as  Brady’s  reagent.
Dinitrophenylhydrazine  is  relatively  sensitive  to shock and friction;  it  is  a  shock
explosive so care must be taken with its use. It is red to orange solid, usually supplied
wet to reduce its explosive hazard. It is a substituted hydrazine, and is often used for
the  determination of  carbonyl  groups associated  with  aldehydes and ketones.  The
reagent was prepared in water for the present study. 
Parachloranilic acid75,76
p-Chloranilic acid mainly involves in the charge transfer reactions. p-CA acts
as a pi acceptor. The interaction of drug with pi-acceptor (p-CA) at room temperature
was found to yield  colored charge transfer complex.  The reagent was prepared in
methanol.
Bratton Marshal reagent (BMR)77,78
Bratton  Marshal  reagent  is  also  called  as  N-(1-naphthyl)  ethylenediamine
dihydrochloride. It was white to light tan or grey crystalline solid or off white powder.
It  was prepared by dissolving in  water.  It  was light  sensitive and hygroscopic.  It
mainly reacts with the compounds containing amine as the functional group.
Potassium ferricyanide79,80
Potassium  ferricyanide  is  used  as  an  oxidizing  agent.  It  was  bright  red,
crystalline powder. It was prepared by dissolving in water. 
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Central nervous system (CNS) acting drugs are widely used to treat various
diseases like Parkinsonism, Schizophrenia,  Mania, Epilepsy, Insomnia,  Depression,
Anxiety,  Meningitis  etc.  A  number  of  novel  drugs  like  Pregabalin,  Zolpidem,
Galantamine, Levetiracetam and Premipexole were reaching the market as an attempt
to treat CNS diseases and disorders. 
Epilepsy is  a  common neurological  condition,  affecting  0.5  to  1% of  the
population worldwide (45-100 million people). The epilepsies are a group of disorders
characterized by chronic recurrent paroxysmal changes in neurologic function caused
by abnormalities  in  the  electrical  activity  of  the  brain.  The  anticonvulsants are  a
diverse  group  of  pharmaceuticals used  in  the  treatment  of  epileptic seizures.
Anticonvulsants  are  often  called  antiepileptic  drugs (abbreviated  "AEDs").  Anti
epileptic drugs decreases the frequency and /or severity, not the underlying epileptic
conditions  and  improves  quality  of  life  by  minimizing  seizures.  The  goal  of  an
anticonvulsant is to suppress the rapid and excessive firing of  neurons that  start a
seizure. Because of this, anticonvulsants also have proven effective in treating many
kinds of dysfunctional anxiety. Failing this, an effective anticonvulsant would prevent
the  spread  of  the  seizure  within  the  brain  and  offer  protection  against  possible
excitotoxic effects that may result in brain damage. 
Classification of Anti Epilleptics81:
1. Barbiturate                       : Phenobarbitone
2. Deoxybarbiturate             : Primidone
3. Hydantoin                         : Phenytoin
4. Iminostillbene                   : Carbamazepine
5. Succinimide                       : Ethosuximide
6. Aliphatic carboxylic acid : Valproic acid
7. Benzodiazepines                : Clonazepam, Diazepam, Clobazam
8. Phenyltriazine                   : Lamotrigine
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9. Cyclic GABA analogue    : Gabapentin
10. Newer drugs                      : Vigabatrin, Tiagabine, Levetiracetam
In the present study we have been selected Levetiracetam and Lamotrigine
for the quantitative determination.  The main purpose of selecting these drugs was
according to the literature survey very few chromatographic and spectrophotometric
method were developed  and still there was lot of scope to develop many analytical
methods for the determination of these drugs.
DRUG PROFILE OF LEVETIRACETAM
Chemistry                     : Levetiracetam is an antiepileptic drug
IUPAC Name     : (αS)-α-ethyl-2-oxo-1-pyrrolidineacetamide
Chemical structure        : 
                                                 
Molecular formula        : C18 H14 N2 O2
Molecular weight          : 170.21
Description                    : White to off-white crystalline powder 
Nature                            : Base - Acetamide derivative
Melting point                 : 1180 C
Solubility                       : Very soluble in water – 104g/100ml
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Isomers                          : A single enantiomer, (-)-(s)-a-ehyl-2-oxo-1 pyrrolidine          
acetamide.
Biotransformation     :  The major metabolism pathway of Levetiracetam (24% of
dose) is an enzymatic hydrolysis of the acetamide group. No
CYP450 metabolism detected.   
Protein binding              : Very low (<10%)    
Volume of distribution  : 0.7 L/kg
Elimination clearance    : 0.96ml/min/kg
T ½                                 : 6-10.3hrs
Kel                                 : 0.099/h
Indications  &  usage   :  Levetiracetam  is  indicated  as  adjunctive  therapy  in  the
treatment of partial onset and in the treatment of myoclonic
seizures. 
Mechanism of Action  : This is a structural analog of piracetam, which binds to a
synaptic vesicle protein SV2A. This is believed to impede
nerve conduction across synapses.
Storage                            : Tightly closed, away from excess heat and moisture
DRUG PROFILE OF LAMOTRIGINE
Chemistry                     : Lamotrigine is an antiepileptic drug
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IUPAC Name               : 6-(2, 3-Dichlorophenyl)-1, 2, 4-triazine-3, 5-diamine
Chemical structure        : 
Molecular formula        : C9H7Cl2N5 
Molecular weight          : 256.091 g/mol
Description                    : White or almost white powder
Nature                            : Base - Acetamide derivative
Melting point                 : 2190 C
Solubility                       : Very slightly soluble in water and soluble in methanol
Biotransformation         : Lamotrigine is metabolized predominantly by glucuronic 
acid  conjugation; the major metabolite is an inactive 2-N-
glucuronide conjugate.
Protein binding              : 55%    
Volume of distribution  : 1.25 - 1.47 L/kg
Elimination clearance    : 0.35-0.59ml/kg
T ½                                 :  24.1- 35 hrs
Kel                                 :  0.099/h
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Indications  & usage    :  Lamotrigine is  indicated as  adjunctive therapy for  partial
seizures,  the  generalized  seizures  of  Lennox-Gastaut
syndrome in adults and pediatric patients (≥2 years of age). 
Mechanism of Action  :  The mechanism of action of lamotrigine is inhibition of the
release  of  excitatory  neurotransmitters  (aspartate  and
glutamate) and also involvement of the blocking of voltage
dependent sodium channels.
Storage                           :  Protected from light
REVIEW OF LITERATURE
LEVETIRACETAM:
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Levetiracetam  is  an  antiepileptic  drug  ((αS)-α-ethyl-2-oxo-1-
pyrrolidineacetamide). It is indicated as adjunctive therapy in the treatment of partial
onset  and  in  the  treatment  of  myoclonic  seizures.  This  is  a  structural  analog  of
piracetam, which binds to a synaptic vesicle protein SV2A. This is believed to impede
nerve conduction across synapses.
Jens  Martens82 et  al reported  a  method  for  the  routine  quantification  of  the  novel
antiepileptic drug levetiracetam in human serum by HPLC with UV detection. Separation was
achieved by elution with diluted phosphoric acid/acetonitrile and it was detected at 205 nm.
Calibration function was linearity in the range of 1-75 mcg/ml. The detection limit was 0.1
mcg/ml interday RSD are lower than 3% and the accuracies are better than 6%. 
Rao83 et al developed a HPLC method for the enantiomeric separation of levetiracetam chiral
pak AD-H column as a stationary phase hexane and isopropanal in the ratio (90:10) used as
mobile phase at a flow rate of 1.0 ml/mt. Limit of detection and limit of quantification were
found to be 900 and 2200 ng/ml respectively. Calibration curve for (R) enantiomer was linear
over studied range (2250-9000) ng with correlation greater than 0.998. Percentage recovery
was ranged from 94.2-102.6 and from 93.5-104.1%.
Tie dong84 et al developed high performance liquid chromatography electro spray tandem
mass spectrometry. C18 column was used for this method. Interday, intraday and precision
was  evaluated  for  levetiracetam  using  for  three  levels  of  in  house  control.  Within  day
coefficient of variation were <60.1% and between day were 8.2% the average recoveries of
levetiracetam were 108%.    
Ratnaraj  N85 et  al developed  an  isocratic  high  performance  liquid  chromatographic
micromethod  for  quantitative  of  levetiracetam  in  plasma.  Lichrospher  60RP  ,  5micron
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column  and  15:85  ratio  of  acetonitrile  phosphate  buffer  were  used as  a  mobile  phase,
detected  at  220  nm  limit  of  quantification  was  5  micron  mole/I  and  within  batch  and
between batch coefficient of variation were<7%.
Isoherranen  N86 et  al developed  a  GC-MS  method  for  enantio  selective  analysis  of
levetiracetam and its enantiomer (R)-alpha ethyl 2-oxo-pyrolidine acetamide in drug plasma
and urine  using  chiral  cyclodextrin capillary  column and ion  trap mass  spectrometry  for
detection.  Calibration  curves  were  linear  from  1  micron  to  2  micron.  RSD  for  interday
precision was 10%.   
Valarmathy J87 et al developed a RP-HPLC method for levetiracetam in which separation was
done by using mobile phase consists of buffer solution (pH 2.8) and acetonitrile in the ratio
of  90:10.  Chromatography  separations  were  carried  out  on  prontosil  C18  column
(150X4.6mn;  5μm)  at  a  flow  rate  of  1.2  ml/min  and  UV  detection  at  215  nm  and  the
retention  time  for  levetiracetam  is  4minutes.  Calibration  curve  was  linear  in  the
concentration range of 45-270 µg/ml and correlation coefficient was found to be 0.999 and
percentage recovery was found to be 98.08%.
Lakshmana  rao  A88 et  al developed  a  RP-HPLC  method  for  levetiracetam  which  is
chromatographed on a reverse phase C18 column in a mobile phase consisting of 0.05 M
KH2PO4 buffer (pH 3.0 adjusted with orthophosphoric acid) and methanol in the ratio 70:30
v/v. The mobile phase was pumped at a flow rate of 1.2 mL/min. with detection at 210 nm.
The  detector  response  was  linear  in  the  concentration  of  20-120  μg/mL.  The  limit  of
detection and limit of quantification was found to be 0.0104 and 0.0317 μg/mL, respectively.
The intra and inter day variation was found to be less than 1%. The mean recovery of the
drug from the solution containing 100 μg/mL was 100.038 μg/mL.
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Appalaraju N89 et al developed a RP-HPLC method for estimation of levetiracetam in tablet
dosage form by RP-HPLC. A Sun Fire C18, 250 x 4.6 mm, 5 μm partical size, with mobile phase
consisting of acetonitrile and 0.03 M potassium dihydrogen phosphate (pH adjusted to 3.0
with orthophosphoric acid) in the ratio of 15:85 v/v was used. The flow rate was 1 mL/min
and the effluents were monitored at 210 nm. The retention time was 5.53 min. The detector
response was linear in the concentration of 20-240 μg/mL. The limit of detection and limit of
quantification was 0.16 and 0.5 μg/mL respectively. 
Laura  Zufia90 et  al developed a  high-performance  liquid  chromatographic  method using
diode array detection for the determination of levetiracetam in human plasma and validated
for  use  in  pharmacokinetic  studies. Separation  of  compounds  was  achieved  using  a
Teknokroma  Tracer  Excel  120  ODS-B  (3  μm,  4.6  mm  i.d.  ×100  mm)  analytical  column
protected  by  a  Teknokroma  ODS  C18  precolumn.  The  chromatographic  separation  was
carried out using a mobile phase consisting of a mixture of 0.01 M potassium dihydrogen
phosphate with 0.6% TEA and acetonitrile in a proportion 90:10 pumped at a constant flow
rate of 1.2 mL/min. The column was maintained at 40 °C and the eluent was monitored at a
wavelength of 205 nm. A weighted 1/x2 quadratic regression model ranging from 0.53 to
107.00 mg/L was selected as the simplest calibration model that maximized the accuracy all
over the range. 
Damodara Rao91 et al developed a simultaneous determination of levetiracetam and its acid
metabolite  (ucb  L057)  in  serum/plasma  by  liquid  chromatography  tandem  mass
spectrometry. The sample is deproteinized with acetonitrile containing Ritonavir as internal
standard, centrifuged and the supernatant diluted with water (1:2 v/v). Sixty microliters of
the supernatant is injected into the LC-MS/MS and Levetiracetam (LEV) and LEV metabolite
separated chromatographically at room temperature employing a Supelco C18 column and a
0.1% formic acid methanol gradient at pH of 2.5. The retention times for LEV metabolite, LEV
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and Ritonavir were 4.50, 5.38 and 9.18 min, respectively. Calibration curves in spiked plasma
were linear over the concentration range of 0–50 μg/mL for LEV and 0.0-5.0 μg/mL for LEV
metabolite. Recoveries of both LEV and LEV metabolite were close to 100%. In this method
LEV and LEV metabolite are separated at pH 2.5. The total run time including the washing
step is 10 min/sample, making this method suitable when moderate throughput is needed
such as in clinical or commercial reference laboratories.
Saravanan  G92 et  al developed  a  LC  Method  for  the  determination  of  the  stability  of
levetiracetam drug substance under stressing conditions. A chromatographic separation was
achieved on a YMC pack ODS AQ, 250 mm × 4.6 mm, 5 µm column using diluted phosphoric
acid and acetonitrile in the ratio 85:15 v/v. The flow rate was 1.0 mL/min, the column was
maintained  at  30˚C  and  the  wavelength  was  set  to  205  nm,  respectively.  The  injection
volume was 10 µL. Forced degradation studies were performed on the levetiracetam drug
substance. The drug substance was degraded to Imp-B during acid and base hydrolysis. The
sample solution and mobile phase was found to be stable up to 48 h at 25 ˚C.
Gaudette F93 et al developed a LC/MS/MS method for the determination of S-Levetiracetam
in  human  plasma. Piracetam  was  added  as  internal  standard.  A  Sciex  API  III  mass
spectrometer equipped with an APCI source is used to detect the analyte as well as internal
standard by selected monitoring in positive ion mode. Analyte quantification is done by peak
area ratio. A quadratic (weighted 1/concentration) was judged to produce the best fit for the
concentration/detector relationship for S-Levetiracetam (correlation coefficient r  ≥  0.9982)
over a concentration range of 100 to 25000 ng/mL. The inter-batch precision and accuracy
for the quality control samples varies from % nominal of 93.9 to 103.0 with a % variation ≤to
12.2. 
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LAMOTRIGINE:
Lamotrigine  is  an  antiepileptic  drug  (6-(2,  3-Dichlorophenyl)-1,  2,  4-triazine-3,  5-
diamine). Lamotrigine is indicated as adjunctive therapy for partial seizures, the generalized
seizures of Lennox-Gastaut syndrome in adults and pediatric (≥2 years of age).
Tuba I94 et al developed a  validated high-performance liquid chromatographic method for
the  determination  of  lamotrigine  (LMT)  in  human  plasma  and  saliva.  Chromatographic
separation was achieved using a 5 μm ACE-5 C18 reverse-phase column and a mobile phase
consisting  of  methanol:acetonitrile:0.01  M  potassium  phosphate  monobasic  (30:15:55,
v/v/v)  adjusted to  pH 6.3  and delivered at  a  flow rate  of  1  mL/min.  Quantification was
performed by measurement of the UV absorbance at a wavelength of 304 nm. The method
was linear in the range of 0.1-6.2 μg/mL with a coefficient of determination, (r2
 
= 0.999). The
retention time of LMT was 6.8 and 6.2 min in plasma and saliva, respectively. The limit of
quantification was 0.10 μg/mL. Recovery from plasma and saliva ranged from 97 to 98 and
96  to  105  %,  respectively.  Between-day  and within  day  precision  expressed as  CV  % in
plasma and saliva were in the range of 0.26 to 6.8. 
JAWAD S95 et al studied on the effect of lamotrigine, a novel anticonvulsant, on interictal
spikes  in  patients  with  epilepsy  using  the  method  of  interictal  EEG spike  counting.  The
method of inter-ictal electroencephalographic (EEG) spike counting has been used to assess
the comparative efficacy of diazepam (20 mg) and lamotrigine (240 mg), both given orally.
Duplicate standards, samples and a control were extracted from alkaline buffer into ethyl
acetate,  and  the  solvent  evaporated  under  nitrogen  at  50°C.  The  resulting  residue  was
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dissolved in ethanol for injection on an automated HPLC system. A 250 x 4.6 mm i.d. silica
column with an ammoniacal ethanol/hexane mobile phase resolved the components which
were detected by UV at 306 nm. The concentration of lamotrigine in the test samples was
determined from their respective internal standard ratios. The lower limit of quantitation
was 50 ng/ml with a 0.2 ml sample size. 
Olga Dominguez-Renedo96 et  al developed  a procedure that  has been optimized for the
determination  of  lamotrigine  by  differential  pulse  adsorptive  stripping  voltammetry
(DPAdSV) using carbon screen-printed electrodes (CSPE) and mercury coated carbon screen-
printed electrodes. The detection limit found was 5.0 x 10-6 M and 2.0 x 10-6 M for the non
modified and Hg modified CSPE, respectively. In terms of reproducibility, the precision of the
above mentioned methods was calculated in %RSD values at 9.83% for CSPE and 2.73% for
Hg-CSPE. 
Pavan  Kumar  P97 et  al developed  a  RP-HPLC  method  for  lamotrigine.  Chromatographic
separation was performed on a Supelco C18 (25cm X 4.6mm and i.d., 5μm) column using a
mobile  phase of methanol  and 0.05 M potassium dihydrogen orthophosphate (65:35v/v)
adjusted the pH 4.5 with dilute orthophosphoric acid. Flow rate of 1 ml/min, column was
maintained at room temperature and the detected by a UV-wave length at 270 nm. The
lamotrigine  was  well  resolved  on  the  stationary  phase  and  the  retention  time  was  3.7
minute. The method was validated and shown to be linear for lamotrigine in 20-100 μg /ml.
The correlation coefficient for lamotrigine is 0.9998 respectively. The method was validated
for  precision,  accuracy;  LOD  and  LOQ  were  determined  to  be  15  ng/ml  and  5  ng/ml
respectively.
Shrivastava PK98 et al developed a quantitative estimation of lamotrigine stress degradation
products using validated RP-HPLC method. Forced degradation studies were performed using
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acid,  base  and  thermal  conditions.  The  separation  of  lamotrigine  from  its  degradation
product was obtained in mobile phase acetonitrile: methanol: 10 M potassium dihydrogen
phosphate buffer (20:20:60, v/v/v) at pH-7. HPLC analytical  measurement and separation
were performed at  phenomenex,  (250 x4.6  mm) Luna 5μ C-18 (2)  100.  A stainless  steel
column using a flow rate of 1.5 ml/min with UV/Vis detector at wavelength 306 nm. The
correlation  coefficient  r2  =  0.9998  was  found in  the  linearity  range  of  2-12 μg/ml.  The
%R.S.D. values for intra-day and inter-day study were < 2.0%.
Soons JWPH99 et al developed a method in which lamotrigine is measured in plasma or dried
blood spots obtained from patients blood by HPLC. The reversed phase HPLC system (Agilent
1100) contains a stationary phase of an ODS Hypersil,  5μm, 100 x 4.6 mm column and a
mobile  phase of a phosphate buffer pH = 7.0 containing 32% methanol.  The lamotrigine
concentration  is  measured  by  a  4-point  standard  curve  of  lamotrigine  and  is  internal
standardized with A725C 78. Lamotrigine can be measured both in plasma as well  as in
whole blood.  Samples of plasma and blood can be exchanged in the same assay. A 20-fold
reduction  in  the  patient  sample  volume  still  gives  an  admissible  reproducibility  in  the
therapeutic range. This indicates that the assay can handle a sample volume (10 µl) that is
generally used in dried blood spots. The inter dot CV obtained in blood of three patients
receiving lamotrigine were 10% or less. 
Manuela Contin100 et al  developed a method allowing the newer antiepileptic drugs (AEDs)
rufinamide (RFN) and zonisamide (ZNS) to be simultaneously determined with lamotrigine
(LTG), oxcarbazepine’s (OXC) main active metabolite monohydroxycarbamazepine (MHD) and
felbamate  (FBM)  in  plasma  of  patients  with  epilepsy  using  high  performance  liquid
chromatography (HPLC) with UV detection. Plasma samples (250 µL) were deproteinized by
1mL acetonitrile spiked with citalopram as internal standard (I.S.). HPLC analysis was carried
out  on  a  Synergi  4  µm Hydro-RP,  250mm×4.6mm  I.D.  column.  The  mobile  phase was  a
                                                                41
mixture  of  potassium  dihydrogen  phosphate  buffer  (50mM,  pH  4.5),  acetonitrile  and
methanol (65:26.2:8.8, v/v/v) at an isocratic flow rate of 0.8 mL/min. The UV detector was
set at 210 nm. Calibration curves were linear for both AEDs over a range of 2-40 µg/mL for
RFN and 2-80µg/mL for ZNS. The limit of quantitation was 2µg/mL for both analytes and the
absolute recovery ranged from 97% to 103% for RFN, ZNS and the I.S. Intra- and interassay
precision and accuracy were lower than 10% at all tested concentrations. 
Mathrusri Annapurna M101 et al developed a stability indicating reverse phase HPLC method
for the determination of lamotrigine on Hypersil ODS C18 column (250 mm × 4 mm, 5 μm). A
mobile phase consisting of methanol: 0.01 mol/L TBAHS (Tetra butyl ammonium hydrogen
sulphate)  (50:50  %  v/v)  was  used.  The  flow  rate  was  1.0  mL/min.  The  separation  was
performed at room temperature. UV detection was carried out at 225 nm. The retention
time of lamotrigine is found to be 3.383 min. The forced degradation studies were conducted
at room temperature by exposing the drug sample (20μg/ml) to 0.05N HCl (acidic), 0.01N
NaOH (alkaline), 5% Hydrogen peroxide (oxidation), UV radiation (photolysis) and at elevated
temperature 50°C (thermal) for one hour. Beer’s Law was obeyed over a concentration range
of 5.0-240 μg/mL and correlation coefficient was 0.999. 
Elizabeth Greiner-Sosanko102 et al developed a simultaneous determination of lamotrigine,
zonisamide,  and  carbamazepine  in  human  plasma  by  high-performance  liquid
chromatography.  Lamotrigine,  carbamazepine,  zonisamide,  and  the  internal  standard
chloramphenicol were extracted from serum or plasma using liquid-liquid extraction under
alkaline conditions into an organic solvent. The separation was performed at 22 °C with a
μBondapak C-18 column. The mobile phase was a mixture of aqueous 30 mM potassium
phosphate buffer (adjusted to pH 3.7 with 5% phosphoric acid) and acetonitrile (65:35) at a
flow rate of 1.2 mL/min. Detection was monitored at 270 nm using a Waters 486 detector.
The  method  was  linear  in  the  range  1–30  μg/mL  for  lamotrigine,  2–20  μg/mL  for
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carbamazepine, and 1–40 μg/mL for zonisamide. Within- and between-run precision studies
demonstrated coefficient of variation < 10% at all tested concentrations. 
Nadia Fayek  Y103 et  al  developed a  spectrophotometric,  TLC and HPLC methods  for  the
determination  of  lamotrigine  in  presence  of  its  impurity.  The  first  method  is
spectrophotometric method using  p-chloranilic acid forming a colored product with  λ  max
519±2 nm over a concentration range of 10- 200 µg/ml with mean accuracy 100.13±0.44%.
The second method is based on TLC separation of the cited drug (Rf  =0.75±0.01) from its
impurity (Rf =0.23±0.01) followed by densitometric measurement of the intact drug spots at
275  nm.  The  separation  was  carried  on  silica  gel  plates  using  ethyl  acetate:  methanol:
ammonia 35% (17: 2: 1 v/v/v) as a mobile phase. The linearity range was 0.5-10 µg/spot with
mean accuracy 99.99±1.33%. The third method is stability-indicating HPLC method based on
separation of lamotrigine from its impurity on a reversed phase C18 column, using a mobile
phase of acetonitrile: methanol: 0.01M potassium orthophosphate (pH 6.7±0.1) (30: 20: 50
v/v/v) at ambient temperature 25±5 °C and UV detection at 275 nm over the concentration
range 1-12 µg/ml with mean accuracy of 99.50±1.30%. 
Rajendraprasad  N104 et  al developed  two  spectrophotometric  methods  for  the
determination of lamotrigine (LMT) both in pure form and in its tablets. The first method
(method A) is based on the formation of a colored ion-pair complex (1:1 drug/dye) of LMT
with  bromocresol  green  (BCG)  at  pH  5.02±0.01  and  extraction  of  the  complex  into
dichloromethane followed by the measurement of the yellow ion-pair complex at 410 nm. In
the second (method B), the drug-dye ion-pair complex was dissolved in ethanolic potassium
hydroxide and the resulting base form of the dye was measured at 620 nm. Beer’s law was
obeyed in the concentration range of 1.5-15 μg/mL and 0.5-5.0 μg/mL for method A and
method B, respectively. 
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Basavaraj  Hiremath105 et  al developed  two  spectrophotometric  methods  for  the
determination  of  ceftazidime  (CFZM)  in  either  pure  form  or  in  its  pharmaceutical
formulations  is  described.  The  first  method  is  based  on  the  reaction  of  3-
methylbenzothiazolin-2-one hydrazone (MBTH) with ceftazidime in the presence of ferric
chloride in acidic medium. The resulting blue complex absorbs at λmax 628 nm. The second
method describes the reaction between the diazotized drug and N-(1-
-naphthyl) ethylenediamine dihydrochloride (NEDA) to yield a purple colored product with λ
max at 567 nm. Beer’s law is obeyed in the range 2-10 and 10-50 μg/ mL for MBTH and NEDA
methods, resp. 
Padmarajaiah Nagaraja106 et al developed a spectrophotometric for the determination of
four phenolic drugs; salbutamol, ritodrine, amoxicillin and isoxsuprine. The method is based
on the oxidation of 2, 4- dinitrophenylhydrazine and coupling of the oxidized product with
drugs to give intensely colored chromogen. Under the proposed optimum condition, beer’s
law  was  obeyed  in  the  concentration  range  of  2.5-17,  2-29,  4-33  and  5-30  μg/mL  for
salbutamol, ritodrine, amoxicillin and isoxsuprine respectively. No interference was observed
from common pharmaceutical adjuvants. The suggested method was further applied for the
determinations of drugs in commercial pharmaceutical dosage forms, which was compared
statistically with reference methods by means of  t- test and F- test and were found not to
differ significantly at 95% confidence level. 
Patel KM107 et al developed three visible spectrophotometric methods (A, B, and C) for the
quantitative estimation of mesalamine in bulk and pharmaceutical dosage forms. Method A
is based on diazotization of mesalamine with nitrous acid, to form diazotized mesalamine
followed by its coupling with N-(1-napthyl) ethylene-diamine dihydrochloride to form a violet
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coloured chromogen with maximum absorption at 552 nm; and it obeyed the Beer’s law in
the concentration range of 2-30 µg/ml. Method B is based on condensation of mesalamine
with PDAB to form Schiff’s base. Method C is based on the reaction with gibb’s reagent in
alkaline pH forms a colored chromogen. 
Ratna Kumari K108 et al developed spectrophotometric methods (method A and B) sfor the
determination  of  cefoperazone  (CPZ)  either  in  raw  material  or  in  pharmaceutical
formulations.  The method  A  is  based  on  the  reaction  of  3-methylbenzothiazolin-2-one
hydrazone (MBTH) with cefoperazone  in the presence of ferric chloride in acidic medium.
The resulting green colored chromogen complex absorbs at λmax 600 nm. Method B is based
on the reaction of  cefoperazone  with ferric chloride and potassium ferricyanide to form a
green colored species  having absorption maxima at  740 nm Beer's  law is  obeyed in  the
concentration range of 4-20 μg/ml for both method A and B. The proposed methods were
successfully  applied  to  the  assay  of  cefoperazone  in  pharmaceutical  preparations  with
recoveries varying from 99.92 to 100.20% (method A) and 98.96 to 100.18% (method B),
with relative standard deviation of 0.414% and 0.853% for method A and B respectively. 
Gadkariem EA109 et al developed a spectrophotometric method for the determination of
methyldopa  in  pharmaceutical  preparations.  The  method  was  based  on the  coupling  of
methyldopa with 2, 6-dichloroquinone-4-chlorimide (DCQ). The absorbance maximum (max)
of the resulted colored product was at 400 nm. Beer’s law was obeyed in concentration
range of 4-20 µg/ml methyldopa. The correlation coefficient was found to be (r2=0.9975).
The  limit  of  detection  and  limit  of  quantification  were  1.1  µg/ml  and  3.21  µg/ml,
respectively. 
Mohammad  Yar  K110 et  al developed  a gas  chromatographic  method  where  ethyl
chloroformate  was  examined  as  a  precolumn  derivatizing  reagent  for  determination  of
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isoniazid (INH) and hydrazine (HZ). Phenylhydrazine (PHZ) was used as an internal standard.
GC  separation  was  carried  out  on  an  HP-5  column  (30  m  ×  0.32  mm  i.d.)  with  flame
ionization detection. The elution was carried out at an initial column temperature of 150˚C
for 1 min at a heating rate of 10˚C/min up to 250˚C, nitrogen flow rate of 4 ml/min and a split
ratio of 10:1, v/v. The linear calibration ranges for INH and HZ were observed between 3.5-
37.5 and 3.5-35 mg/ml with corresponding detection limits of 0.18 and 0.17 ng reaching the
detector.  The method was  subsequently  applied  to  the determination  of  INH and HZ in
pharmaceutical preparations, achieving a relative standard deviation (RSD) of 3.8-5.8%. The
recovery percentage of INH from isoniazid syrup was 98% with an RSD of 5.2%.
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OBJECTIVE OF THE PRESENT WORK
             The primary objective of the proposed work was to
 Develop  new,  simple,  sensitive,  accurate,  and  economical  spectrophotometric
methods for the estimation of anti-epileptics in bulk and pharmaceutical formulations.
 Develop new, sensitive, accurate and economical gas chromatography methods for
estimation of anti-epileptics in bulk and pharmaceutical formulations.
 Validate  the  developed  methods  and  apply  them for  estimation  of  commercially
available formulations.
Levetiracetam and lamotrigine are the drugs belonging to CNS category which
are  used  against  epilepsy. Levetiracetam is  indicated  as  adjunctive  therapy in  the
treatment of partial onset and in the treatment of myoclonic seizures. Lamotrigine is
indicated  as  adjunctive  therapy  for  partial  seizures,  the  generalized  seizures  of
Lennox-Gastaut syndrome in adults and pediatric patients.
Literature  survey  reveals  that  very  few  methods  have  been  developed  for
levetiracetam  and  lamotrigine.  In  the  present  investigation  attempts  are  made  to
develop  some new spectrophotometric  methods and  chromatographic  methods  for
levetiracetam  and  lamotrigine,  which  are  highly  sensitive,  accurate,  precise  and
economical. Since very few analytical methods have been reported for the quantitative
estimation  of  these  drugs,  it  is  necessary  for  the  investigation  of  new analytical
methods  for  estimation  of  levetiracetam  and  lamotrigine  in  bulk  drugs  and
pharmaceutical formulations.
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Validation of the methods was carried out in accordance with ICH guideline
for the assay of  active ingredients.  The method was validated for  parameters  like
accuracy, linearity, precision, specificity, system suitability.
The primary objective of validation in the analysis of a drug is to design and
develop methods preferably instrumental ones such as UV spectrophotometric / GC
that  are  sensitive  and  reproducible,  when  applied  for  analysis  of  marketed
formulations.
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MATERIALS AND METHODS
PART A: UV-VISIBLE SPECTROPHOTOMETRIC METHODS FOR 
LEVETIRACETAM
METHOD 1: Estimation of levetiracetam by MBTH reagent
METHOD 2: Estimation of levetiracetam by 2, 4- DNP reagent
METHOD 3: Estimation of levetiracetam by BM reagent
METHOD 4: Estimation of levetiracetam by p-CA reagent
METHOD 5: Estimation of levetiracetam by Potassium ferricyanide 
UV-VISIBLE SPECTROPHOTOMETRIC METHODS FOR LAMOTRIGINE
METHOD 6: Estimation of lamotrigine by Gibb’s reagent
METHOD 7: Estimation of lamotrigine by MBTH reagent
METHOD 8: Estimation of lamotrigine by BM reagent
PART B: GAS CHROMATOGRAPHY METHODS
METHOD 9: Derivatization of levetiracetam by Gas chromatography
METHOD 10: Derivatization of lamotrigine by Gas chromatography
                                                                49
PART A: UV- VISIBLE SPECTROPHOTOMETRIC METHODS
METHOD 1: ESTIMATION OF LEVETIRACETAM BY MBTH REAGENT
1.1 PRINCIPLE INVOLVED
Levetiracetam possess aliphatic amine group and keto group. Where as in the present
reaction aliphatic amine group reacts with MBTH reagent in the presence of FeCl3.
Actually, this is an iron catalyzed oxidative coupling reaction of MBTH with the drug.
Under  the  reaction  conditions,  on  oxidation, MBTH loses  two  electrons  and  one
proton forming an electrophilic intermediate,  which is  the active coupling species.
This intermediate undergoes electrophilic substitution with the drug to form the green
colored product (Scheme 1) with absorption maximum at 634 nm.
1.2 REACTION INVOLVED 
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1.3 REAGENTS USED
1.3.1 3-Methyl-2-Benzthiazolinone hydrochloride (MBTH) 0.5 %( w/v)
0.5 g of MBTH reagent was accurately weighed transferred into a 100 mL calibrated
flask, dissolved in distilled water and make up the volume up to the mark to obtain a
solution of 0.5 %  ( w/v).
1.3.2 Ferric chloride (1%)
Freshly prepared by dissolving 1 g of ferric chloride in 100 mL of distilled water.
1.4 PREPARATION OF STANDARD CALIBRATION CURVE 
1.4.1 Preparation of standard stock solution
Accurately weighed 100 mg of levetiracetam (bulk drug) was dissolved in 50 mL of
methanol in 100 mL volumetric flask and sonicated for about 15 min to enhance the
solubility and  volume was  made upto  to  the  mark  with  methanol  to  obtain  final
concentration of 1000 µg/mL.
1.4.2 Preparation of calibration curve
Standard solutions of LEV in methanol, having final concentrations in the range of
20-100 µg/mL were transferred into a series of 10 mL volumetric flasks.  To each 2
mL of MBTH reagent, 2 mL of ferric chloride was added and the volume was made
up to mark with distilled water and allowed to stand for 20 minutes. The contents
were diluted up to 10 mL with water. The colored species was stable for 2 hours. The
absorption  spectrum of  LEV was  done  and  it  showed  634  nm  as  the  maximum
absorption point (Fig.1). The calibration curve was constructed by plotting absorbance
against the concentration of LEV. The linearity range or Beer’s range follows in the
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range between 20-100 µg/mL (Fig.2). The content of LEV was calculated from the
calibration graph.
1.5 ANALYSIS OF TABLET DOSAGE FORM
Twenty  tablets  (Torleva-250mg)  were  weighed,  powdered  and  their  contents  are
mixed thoroughly. An accurately weighed portion of powder equivalent to the 100 mg
of LEV was weighed into a 100 mL volumetric flask containing about 50 mL of
methanol. It  was shaken thoroughly for about 5-10 minutes, filter thoroughly with
whatman  filter  paper  to  remove  insoluble  matter  and  diluted  to  the  mark  with
methanol to prepare 1000 µg/mL solution. An aliquot of this solution was diluted with
water to obtain a concentration of 40 µg/mL and then the resultant solution is also
analysed as per the procedure and were statically validated.  
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Fig.1. Absorption spectra of LEV on reaction with MBTH
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2. Calibration graph of LEV (20-100µg/ml) on reaction with MBTH
METHOD 2: ESTIMATION OF LEVETIRACETAM BY 2, 4- DNP REAGENT
2.1 PRINCIPLE INVOLVED
In this reaction 2, 4-DNP reagent is oxidized by potassium iodate to give diazonium
cation  which  reacts  with  drug  by  electrophilic  substitution  to  give  deep  colored
chromogen  (Scheme  2).  The  reaction  results  in  a  red  coloured  complex  with
absorption maximum at 455 nm.
2.2 REACTION INVOLVED 
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2.3 REAGENTS USED
2.3.1 2, 4-Dinitrophenyl hydrazine (2, 4-DNP) 0.08 %( w/v)
A 0.08 % w/v of the reagent solution was freshly prepared by dissolving 0.08 g of 2,
4-DNP reagent in 2 mL of concentrated H2SO4 and diluting to 100 mL with water.
2.3.2 10N Sodium hydroxide solution
40 g of sodium hydroxide was dissolved in 100 mL of distilled water.
2.3.3 Potassium iodate 4 % (w/v)
A 4 % w/v potassium iodate solution was prepared by dissolving 4 g in 100 mL of
distilled water.
2.4 PREPARATION OF STANDARD CALIBRATION CURVE 
2.4.1 Preparation of standard stock solution
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Accurately weighed 100 mg of levetiracetam (bulk drug) was dissolved in 50 mL of
methanol in 100 mL volumetric flask and sonicated for about 15 min to enhance the
solubility  and  volume  was  made  upto  to  the  mark  with  methanol  to  obtain  a
concentration of 1000 µg/mL.
2.4.2 Preparation of calibration curve
Standard solutions of LEV in methanol, having final concentrations in the range of
30-130 µg/mL were transferred into a series  of 10 mL volumetric flasks,  to these
solutions 1.5 mL of 2,4-DNP reagent (0.08%) and 1.5 mL of KIO3 (4% )were added,
which were made alkaline by adding 1 mL each of NaOH (10 N). The red color hence
developed was further diluted to the volume with water. The reaction was allowed to
proceed  at  room temperature.  The  absorption  spectrum  of  LEV was  done  and  it
showed 455 nm as the maximum absorption point (Fig.3). The calibration curve was
constructed by plotting absorbance against the concentration of LEV. The linearity
range  or  Beer’s  range  follows  in  the  range  between  30-130  µg/mL (Fig.4). The
content of LEV was calculated from the calibration graph.
2.5 ANALYSIS OF TABLET DOSAGE FORM
Twenty tablets were weighed, powdered and their contents are mixed thoroughly. An
accurately weighed portion of powder equivalent to the 100 mg of LEV was weighed
into a 100 mL volumetric flask containing about 50 mL of methanol. It was shaken
thoroughly for  about  5-10 minutes,  filter  thoroughly with whatman filter  paper  to
remove  insoluble  matter  and  diluted  to  the  mark  with  methanol  to  prepare  1000
µg/mL solution.  An  aliquot  of  this  solution  was  diluted  with  water  to  obtain  a
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concentration of 60 µg/mL and then the resultant solution is also analysed as per the
procedure and was statically validated.  
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Fig.3. Absorption spectra of LEV on reaction with 2, 4 –DNP reagent
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Fig.4. Calibration graph of LEV (30-130µg/ml) on reaction with 2, 4 –DNP 
METHOD 3: ESTIMATION OF LEVETIRACETAM BY BM REAGENT
3.1 PRINCIPLE INVOLVED
It is based on diazotization of drugs with nitrous acid, to form diazotized compound,
followed  by  its  coupling  with  N-(1-naphthyl)  ethylene-  diamine  dihydrochloride
[Bratton-Marshal Reagent] (Scheme 3) with absorption maximum at 461 nm.
3.2 REACTION INVOLVED 
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3.3 REAGENTS USED
3.3.1 2N HCl
It was prepared by dissolving 8.5 mL of hydrochloric acid in 100 mL of water.
3.3.2 Sodium nitrite 0.3 % (w/v)
A 0.3 % (w/v) sodium nitrite was prepared by dissolving 0.3 g in 100 mL of distilled
water.
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3.3.3 Ammonium sulfamate 0.1 % (w/v)
A 0.1 % (w/v) ammonium sulfamate was prepared by dissolving 0.1 g in 100 mL of
distilled water.
3.3.4 N-(1-naphthyl) ethylene- diamine dihydrochloride [BMR] 0.2 % (w/v)
A 0.2 % (w/v) BM reagent was prepared by dissolving 0.2 g in 100 mL of distilled
water.
3.4 PREPARATION OF STANDARD CALIBRATION CURVE 
3.4.1 Preparation of standard stock solution
Accurately weighed 100 mg of levetiracetam (bulk drug) was dissolved in 50 mL of
methanol in 100 mL volumetric flask and sonicated for about 15 min to enhance the
solubility and volume was made upto to the mark with methanol to obtain a final
concentration of 1000 µg/mL.
3.4.2 Preparation of calibration curve
Standard solutions of LEV in methanol, having final concentrations in the range of
50-350 µg/mL were transferred into a series of 10 mL volumetric flasks.  To each
flask, 1.0 mL of hydrochloric acid (2 N) and 1.0 mL of sodium nitrite (0.3 % w/v)
were added and a reaction time of 10 minutes to these solutions at 0-5˚ C was given
for the completion of the reaction. Next, 1.0 mL of ammonium sulfamate (0.1 % w/v)
was added to each flask with gentle shaking after 1 minute, 1 mL of BM reagent (0.2
% w/v) was added, and kept for 20 minutes. Finally the volume in each flask was
brought up to the 10 mL mark with distilled water. The absorption spectrum of LEV
was  done  and  it  showed  461  nm as  the  maximum absorption  point  (Fig.5). The
calibration curve was constructed by plotting absorbance against the concentration of
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LEV. The linearity range or Beer’s range follows in the range between 50-350 µg/mL
(Fig.6). The content of LEV was calculated from the calibration graph.
3.5 ANALYSIS OF TABLET DOSAGE FORM
Twenty tablets were weighed, powdered and their contents are mixed thoroughly. An
accurately weighed portion of powder equivalent to the 100 mg of LEV was weighed
into a 100 mL volumetric flask containing about 50 mL of methanol. It was shaken
thoroughly for  about  5-10 minutes,  filter  thoroughly with whatman filter  paper  to
remove  insoluble  matter  and  diluted  to  the  mark  with  methanol  to  prepare  1000
µg/mL solution. An aliquot of these solutions were diluted with water to obtain a
concentrations of 50 µg/mL and then the resultant solution is also analysed as per the
procedure and was statically validated.  
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Fig.5. Absorption spectra of LEV on reaction with BM reagent
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Fig.6. Calibration graph of LEV (50-350 µg/ml) on reaction with BM reagent
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METHOD 4: ESTIMATION OF LEVETIRACETAM BY p-CA REAGENT
4.1 PRINCIPLE INVOLVED
The interaction of  levetiracetam with pi-acceptor  (p-CA) at  room temperature  was
found to yield colored charge transfer complex. In polar solvents, complete electron
transfer from levetiracetam (D), as an electron donor, to the acceptor moiety (A) takes
place resulting in the formation of intensely colored radical anions (Scheme 4) with
absorption maximum at 440 nm.
4.2 REACTION INVOLVED 
Scheme 4: Reaction of p-CA and LEV
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4.3 REAGENTS USED
4.3.1 p-Chloranilic acid (p-CA) 0.042 % (w/v)
A 0.042 % w/v of the reagent solution was freshly prepared by dissolving 42 mg of p-
CA in 100 mL of acetone.
4.4 PREPARATION OF STANDARD CALIBRATION CURVE 
4.4.1 Preparation of standard stock solution
Accurately weighed 100 mg of levetiracetam (bulk drug) was dissolved in 50 mL of
acetone in 100 mL volumetric flask and sonicated for about 15 min to enhance the
solubility and  volume was  made upto  to  the mark  with acetone to  obtain  a  final
concentration of 1000 µg/mL.
4.4.2 Preparation of calibration curve
Standard solutions of LEV in acetone, having final concentrations in the range of 50-
350 µg/mL were transferred into a series of 10 mL volumetric flasks. To each 3 mL of
p-CA reagent, was added and the volume was made up to mark with acetone. The
colored  product  was  formed  immediately  at  room  temperature  (25±10C).  The
absorption  spectrum of  LEV was  done  and  it  showed  440  nm  as  the  maximum
absorption point (Fig.7). The calibration curve was constructed by plotting absorbance
against the concentration of LEV. The linearity range or Beer’s range follows in the
range between 50-350 µg/mL (Fig.8). The content of LEV was calculated from the
calibration graph.
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4.5 ANALYSIS OF TABLET DOSAGE FORM
Twenty tablets were weighed, powdered and their contents are mixed thoroughly. An
accurately weighed portion of powder equivalent to the 100 mg of LEV was weighed
into a 100 mL volumetric flask containing about 50 mL of acetone. It  was shaken
thoroughly  for  about  5-10  min,  filtered  through  whatman  filter  paper  to  remove
insoluble matter and diluted to the mark with acetone to prepare 1000 µg/mL solution.
An aliquot of this solution was diluted with acetone to obtain a concentration of 100
µg/mL and then the resultant solution is also analysed as per the procedure and was
statically validated.
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Fig.7. Absorption spectra of LEV on reaction with p-CA
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Fig.8. Calibration graph of LEV (50-350µg/ml) on reaction with p-CA
METHOD 5: ESTIMATION OF LEVETIRACETAM BY POTASSIUM 
FERRICYANIDE
5.1 PRINCIPLE INVOLVED
The reaction was based on reduction of  the Fe3+ in  FeCl3 to  Fe2+ by LEV  in the
presence of K3Fe (CN6). Subsequently, the in situ formed Fe2+ reacts with K3Fe (CN6)
under acidic conditions to form soluble prussian blue (KFeIII [FeII (CN) 6]) (Scheme
5) with absorption maximum at 750 nm.
5.2 REACTION INVOLVED 
Aliphatic-NH2 + Fe3+  Fe2+
                                                                                    
      3 Fe2+      +       2 [K 3Fe (CN) 6]3-                                                 [K Fe 3[Fe2 (CN) 6]2
                     Potassium ferricyanide                        colored complex
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HCL
Scheme 5: Reaction of potassium ferricyanide and LEV
5.3 REAGENTS USED
5.3.1 Ferric chloride 0.5% (w/v)
A 0.5 % w/v ferric chloride was freshly prepared by dissolving 500 mg in 100 mL of
distilled water.
5.3.2 Potassium ferricyanide 0.1% (w/v)
A 0.1 % Potassium ferricyanide was prepared by dissolving 100 mg in 100 mL of
distilled water.
5.3.3 1 N HCl:
It was prepared by dissolving 4.25 mL of HCL in 100 mL of water.
5.4 PREPARATION OF STANDARD CALIBRATION CURVE 
5.4.1 Preparation of standard stock solution
Accurately weighed 100 mg of levetiracetam (bulk drug) was dissolved in 50 mL of
methanol in 100 mL volumetric flask and sonicated for about 15 min to enhance the
solubility and volume was made upto to the mark with methanol to obtain a final
concentration of 1000 µg/mL.
5.4.2 Preparation of calibration curve
Standard solutions of LEV in methanol, having final concentrations in the range of
100-400 µg/mL were transferred into a series of 10 mL volumetric flasks. To each 1.5
mL of ferric chloride ( 0.5%), and 0.5 mL of potassium ferricyanide (0.1%)  and 1 mL
of 1 N HCL were added and the volume was made up to mark with water. The colored
product  was  formed  immediately  at  room  temperature  (25±10c).  The  absorption
spectrum of LEV was done and it showed 750 nm as the maximum absorption point
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(Fig.9). The  calibration  curve  was  constructed  by plotting  absorbance  against  the
concentration  of  LEV.  The  linearity  range  or  Beer’s  range  follows  in  the  range
between  100-400  µg/mL (Fig.10). The  content  of  LEV was  calculated  from  the
calibration graph.
5.5 ANALYSIS OF TABLET DOSAGE FORM
Twenty tablets were weighed, powdered and their contents are mixed thoroughly. An
accurately weighed portion of powder equivalent to the 100 mg of LEV was weighed
into a 100 mL volumetric flask containing about 50 mL of methanol. It was shaken
thoroughly for about 5-10 min, filter thoroughly with whatman filter paper to remove
insoluble  matter  and  diluted  to  the  mark  with  methanol  to  prepare  1000  µg/mL
solution.  An  aliquot  of  this  solution  was  diluted  with  methanol  to  obtain  a
concentration of 100 µg/mL and then the resultant solution is also analysed as per the
procedure and was statically validated.
400 800 1200
0
0.1
0.2
0.3
0.4
0.5
0.6
Fig.9. Absorption spectra of LEV on reaction with potassium ferricyanide
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Fig.10. Calibration graph of LEV (100-400 µg/ml) on reaction with potassium
ferricyanide
UV-VISIBLE SPECTROPHOTOMETRIC METHODS FOR LAMOTRIGINE
METHOD 6: ESTIMATION OF LAMOTRIGINE BY GIBB’S REAGENT
6.1 PRINCIPLE INVOLVED
Lamotrigine possess aliphatic amine group. An attempt has been made to determine
lamotrigine by reacting at the amine group. Oxidation of lamotrigine was attempted in
the present study. The first method is based on the reaction between the Gibb’s reagent
and LMT. The Gibb’s reagent reacts with LMT and results in the formation of color
complex (Scheme 6) with absorption maximum at 403 nm.
6.2 REACTION INVOLVED 
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Scheme 6: Reaction of Gibb’s reagent and LMT
6.3 REAGENTS USED
6.3.1 2, 6-Dichloroquinone-chlorimide reagent 0.5 %( w/v)
It was prepared by dissolving 0.5 g of Gibb’s reagent in 100 mL of methanol. 
6.4 PREPARATION OF STANDARD CALIBRATION CURVE 
6.4.1 Preparation of standard stock solution
Accurately weighed 100 mg of lamotrigine (bulk drug) was dissolved in 50 mL of
methanol in 100 mL volumetric flask and sonicated for about 15 min to enhance the
solubility and volume was made upto to the mark with methanol to obtain a final
concentration of 1000 µg/mL.
6.4.2 Preparation of calibration curve
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Standard solutions of LMT in methanol, having final concentrations in the range of
50-350 µg/mL were transferred into a series  of 10 mL volumetric flasks,  to these
solutions; 1 mL of 0.5% Gibb’s reagent is added. The mixture was then heated for 15
minutes.  The  contents  were  diluted  up  to  10  mL with  methanol.  The  absorption
spectrum of LMT was done and it showed 403 nm as the maximum absorption point
(Fig.11). The calibration curve was constructed by plotting absorbance against  the
concentration  of  LMT.  The  linearity  range  or  Beer’s  range  follows  in  the  range
between  50-350  µg/mL (Fig.12). The  content  of  LMT  was  calculated  from  the
calibration graph.
6.5 ANALYSIS OF TABLET DOSAGE FORM
Twenty  tablets  (Lamitor-50  mg)  were  weighed,  powdered  and  their  contents  are
mixed thoroughly. An accurately weighed portion of powder equivalent to the 100 mg
of LMT was weighed into a 100 mL volumetric flask containing about 75 mL of
methanol.  It  was  shaken  thoroughly  for  about  5-10  min,  filter  thoroughly  with
whatman  filter  paper  to  remove  insoluble  matter  and  diluted  to  the  mark  with
methanol to prepare 1000 µg/ml solution. An aliquot of the above solution was diluted
with methanol to obtain a concentration of 50 µg/ml and then the resultant solution is
also analysed as per the procedure and was statically validated.
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Fig.11. Absorption spectra of LMT on reaction with Gibb’s reagent
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Fig.12. Calibration graph of LMT (50- 350 µg/ml) on reaction with  
Gibb’s reagent
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METHOD 7: ESTIMATION OF LAMOTRIGINE BY MBTH REAGENT
7.1 PRINCIPLE INVOLVED
In  the  present  reaction  aliphatic  amine  group  reacts  with  MBTH  reagent  in  the
presence of ferric chloride. This is an iron catalyzed oxidative coupling reaction of
MBTH with the drug. Under the reaction conditions, on oxidation, MBTH loses two
electrons and one proton forming an electrophilic intermediate, which is the active
coupling species. This intermediate undergoes electrophilic substitution with the drug
to form the green colored product (Scheme 7) with absorption maximum at 662 nm.
7.2 REACTION INVOLVED 
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Scheme 7: Reaction of MBTH reagent and LMT
7.3 REAGENTS USED
7.3.1 3-Methyl-2-Benzthiazolinone hydrochloride (MBTH) 0.5 %( w/v)
0.5 g of MBTH reagent was accurately weighed transferred into a 100 mL calibrated
flask, dissolved in distilled water and make up the volume up to the mark to obtain a
solution of 0.5 %  ( w/v).
7.3.2 Ferric chloride (1%)
Freshly prepared by dissolving 1 g of ferric chloride in 100 mL of distilled water.
7.4 PREPARATION OF STANDARD CALIBRATION CURVE 
7.4.1 Preparation of standard stock solution
Accurately weighed 100 mg of lamotrigine (bulk drug) was dissolved in 50 mL of
methanol in 100 mL volumetric flask and sonicated for about 15 min to enhance the
solubility and volume was made upto to the mark with methanol to obtain a final
concentration of 1000 µg/mL.
7.4.2 Preparation of calibration curve
Standard solutions of LMT in methanol, having final concentrations in the range of
25-350 µg/mL were transferred into a series of 10 mL volumetric flasks.  To each 2
mL of MBTH reagent (0.5%), 2 mL of ferric chloride (1%) was added and the volume
was made up to the mark with distilled water and allowed to stand for 20 minutes.
The contents were diluted up to 10 mL with water. The colored species was stable for
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2 hours. The absorption spectrum of LMT was done and it showed 662 nm as the
maximum  absorption  point  (Fig.13). The  calibration  curve  was  constructed  by
plotting absorbance against the concentration of LMT. The linearity range or Beer’s
range follows in the range between 25- 350 µg/mL (Fig.14). The content of LMT was
calculated from the calibration graph.
7.5 ANALYSIS OF TABLET DOSAGE FORM
Twenty tablets were weighed, powdered and their contents are mixed thoroughly. An
accurately weighed portion of powder equivalent to the 100 mg of LMT was weighed
into a 100 mL volumetric flask containing about 75 mL of methanol. It was shaken
thoroughly for  about  5-10 minutes,  filter  thoroughly with whatman filter  paper  to
remove  insoluble  matter  and  diluted  to  the  mark  with  methanol  to  prepare  1000
µg/mL solution.  An  aliquot  of  this  solution  was  diluted  with  water  to  obtain  a
concentration of 40 µg/mL and then the resultant solution is also analysed as per the
procedure and were statically validated.  
400 500 600 700 800 900 1000
0
0.1
0.2
0.3
0.4
0.5
Fig.13. Absorption spectra of LMT on reaction with MBTH
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Fig.14. Calibration graph of LMT (25-350 µg/ml) on reaction with MBTH
METHOD 8: ESTIMATION OF LAMOTRIGINE BY BM REAGENT
8.1 PRINCIPLE INVOLVED
It is based on diazotization of drugs with nitrous acid, to form diazotized compound,
followed  by  its  coupling  with  N-(1-naphthyl)  ethylene-  diamine  dihydrochloride
[Bratton-Marshal reagent] (Scheme 8) with absorption maximum at 461 nm.
8.2 REACTION INVOLVED 
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Scheme 8: Reaction of BM reagent and LMT
8.3 REAGENTS USED
8.3.1 2N HCl
It was prepared by dissolving 8.5 mL of hydrochloric acid in 100 mL of water.
8.3.2 Sodium nitrite 0.3 % (w/v)
A 0.3% (w/v) sodium nitrite was prepared by dissolving 0.3 g in 100 mL of distilled
water.
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8.3.3 Ammonium sulfamate 0.1 % (w/v)
A 0.1 % (w/v) ammonium sulfamate was prepared by dissolving 0.1 g in 100 mL of
distilled water.
8.3.4 N-(1-naphthyl) ethylene- diamine dihydrochloride [BMR] 0.2 % (w/v)
A 0.2 % (w/v) BM reagent was prepared by dissolving 0.2 g in 100 mL of distilled
water.
8.4 PREPARATION OF STANDARD CALIBRATION CURVE 
8.4.1 Preparation of standard stock solution
Accurately weighed 100 mg of lamotrigine (bulk drug) was dissolved in 50 mL of
methanol in 100 mL volumetric flask and sonicated for about 15 min to enhance the
solubility and volume was made up to  the mark with methanol  i.e. 1000 µg/mL.
8.4.2 Preparation of calibration curve
Standard solutions of LMT in methanol, having final concentrations in the range of
50-350 µg/mL were transferred into a series of 10 mL volumetric flasks.  To each
flask, 1.0 mL of hydrochloric acid (2 N) and 1.0 mL of sodium nitrite (0.3 % w/v)
were added and a reaction time of 10 minutes to these solutions at 0-5˚ C was given
for the completion of the reaction. Next, 1.0 mL of ammonium sulfamate (0.1 % w/v)
was added to each flask with gentle shaking after 1 minute, 1 mL of BM reagent (0.2
% w/v) was added, and kept for 20 minutes. Finally the volume in each flask was
brought up to the 10 mL mark with distilled water. The absorption spectrum of LMT
was  done and it  showed 461 nm as  the  maximum absorption point  (Fig.15). The
calibration curve was constructed by plotting absorbance against the concentration of
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LMT. The linearity range or Beer’s range follows in the range between 50- 350µg/mL
(Fig.16). The content of LMT was calculated from the calibration graph. 
8.5 ANALYSIS OF TABLET DOSAGE FORM
Twenty tablets were weighed, powdered and their contents are mixed thoroughly. An
accurately weighed portion of powder equivalent to the 100 mg of LMT was weighed
into a 100 mL volumetric flask containing about 50 mL of methanol. It was shaken
thoroughly for  about  5-10 minutes,  filter  thoroughly with whatman filter  paper  to
remove  insoluble  matter  and  diluted  to  the  mark  with  methanol  to  prepare  1000
µg/mL solution. An aliquot of these solutions were diluted with water to obtain a
concentrations of 50 µg/mL and then the resultant solution is also analysed as per the
procedure and was statically validated.
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Fig.15. Absorption spectra of LMT on reaction with BMR
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Fig.16. Calibration graph of LMT (50-350 µg/ml) on reaction with BMR
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PART B: GAS CHROMATOGRAPHY METHODS
METHOD  9:  DERIVATIZATION  OF  LEVETIRACETAM  BY  GAS
CHROMATOGRAPHY
9.1 PRINCIPLE INVOLVED
Alkyl  chloroformates  have  been  used  as  derivatizing  reagents  for  Gas
chromatographic  (GC)  determinations  of  amines,  amino  acids,  amino  alcohol  and
acids.  Levetiracetam possess aliphatic amine group and keto group. An attempt has
been made to determine levetiracetam by reacting at the amine group. LEV reacted
with ethylchloroformate reagent to form volatile products and eluted from a capillary
GC column, each as single peak. The reaction was carried out in methanol, aqueous
solution containing a pyridine base, and chloroform was used for the extraction of the
derivatives.
9.2 REACTION INVOLVED 
Scheme 9: Structure of the derivative ECF (a) ECF (b) Derivatized product
9.3 INSTRUMENTATION
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Gas chromatography studies were carried out on SHIMADZU model 2014 (Shimadzu
Technologies, Japan) coupled with a split/split less injector and FID. The computer
with GC solutions software has been used to control the gas chromatograph. Rtx-5
capillary column (cross bond 5% diphenyl/95% dimethyl polysiloxane) with a length
of 30 meters and an internal diameter of 0.25 mm was used throughout the study.
9.4 CHEMICALS AND REAGENTS
Analysis  was  performed  on  methanol  solutions  of  LEV.  All  the  standards  were
supplied  by Sigma  and  met  Pharamcopoeial  requirements.  Methanol  of  analytical
quality was procured from MERCK (Worli, Mumbai).
9.5 PREPARATION OF WORKING STOCK SOLUTION 
Levetiracetam solution at a concentration of 1 mg/ml was prepared in HPLC grade
methanol and diluted to obtain serial dilutions from 2 to 10 ng/ml. The solutions were
kept at below 5˚C and were protected from light. 
9.6 CHROMATOGRAPHIC CONDITIONS
The GC-FID parameters used in the method development were based on the boiling
point of the drug. The injection port and detector temperature were set to 170˚C and
250˚C, respectively. Different temperature programs were investigated for GC oven.
Best program temperature resolution was selected for a good resolution at end of the
investigation. 
Manual splitless injection of approximately 2-µl sample was performed at an
inlet  temperature  of  170˚C.  The  detector  temperature  was  set  to  250˚C.  After
injection, the oven temperature was increased from 80˚C to 180˚C at a rate of 100˚C
per min for 5min. The initial carrier gas (nitrogen) pressure was maintained at 29.8
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Kpa for 3.5 minutes and pressure was increased at a rate of 20Kpa/min up to 120Kpa
and held constant for 4.50 min.
Synthetic air (flow rate of 100 ml/min), hydrogen (25 ml/min) were fed to the
FID. All the gases used in these studies were of Pharamcopoeial purity. 
LEV analysis was performed after derivatization, LEV is a polar molecule and
therefore,  a polar solvent methanol was used as the diluent.  The capillary column
coated with 5% diphenyl/ 95% dimethyl polysiloxane is a good choice for separation
of  this  analyte  since  they  elute  as  symmetrical  peaks  at  a  wide  range  of
concentrations.
9.7 ASSAY
Standard solutions of LEV in HPLC grade methanol, having final concentrations in
the range of 2-10 ng/mL were prepared. The drug solution and ECF were added in 1:1
ratio. The solution was heated at 700 C for 5 minutes. Solution was evaporated after
addition  of  pyridine  and  chloroform.  Upper  layer  was  collected,  redissolved  in
methanol. Two µl aliquot of each derivatized sample solution was injected on to the
column  and  the  chromatogram  (Fig.17). was  recorded.  Calibration  graph  was
constructed  by  plotting  the  mean  peak  area  as  a  function  of  Levetiracetam
concentration (Fig.18).
9.8 ANALYSIS OF TABLET DOSAGE FORM
Twenty tablets were weighed, powdered and their contents are mixed thoroughly. An
amount of powder equivalent to 10 mg  of a tablet was mixed with methanol and
shaken  for  20  min  at  a  frequency  of  approximately 3  cycle’s/s  in  sonicator.  The
solution was then filtered through 0.45 µm membrane filter. The drug solution and
ECF were added in 1:1 ratio. The solution was heated at 700 C for 5 minutes. Solution
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was evaporated after addition of pyridine and chloroform. Upper layer was collected,
redissolved in methanol and then the chromatogram is shown in Fig. 19.
Fig.17. Chromatogram obtained from pure Levetiracetam (LEV) solution,
Methanol (A), ethyl chloroformate (B), levetiracetam (C)
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Fig.18. Calibration graph of LEV (2-10 ng/ml) on reaction with ECF
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Fig.19. Chromatogram obtained from formulation of Levetiracetam (LEV)
tablet solution. Methanol (A), ethyl chloroformate (B), levetiracetam (C).
METHOD  10:  DERIVATIZATION  OF  LAMOTRIGINE  BY  GAS
CHROMATOGRAPHY
10.1 PRINCIPLE INVOLVED
Alkyl  chloroformates  have  been  used  as  derivatizing  reagents  for  gas
chromatographic  (GC)  determinations  of  amines,  amino  acids,  amino  alcohol  and
acids.  Lamotrigine  possess  aliphatic  amine  group.  An  attempt  has  been  made  to
determine  lamotrigine  by  reacting  at  the  amine  group.  Lamotrigine  reacted  with
ethylchloroformate reagent to form volatile products and eluted from a capillary GC
column,  each  as  single  peak.  The  reaction  was  carried  out  in  methanol,  aqueous
solution containing a pyridine base, and chloroform was used for the extraction of the
derivatives.
10.2 REACTION INVOLVED 
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10.3 PREPARATION OF WORKING STOCK SOLUTION 
Lamotrigine solution at  a  concentration of  1 mg/ml was prepared in HPLC grade
methanol and diluted to obtain serial dilutions from 2 to 10 ng/ml. The solutions were
kept at below 5˚C and were protected from light. 
10.4 CHROMATOGRAPHIC CONDITIONS
The GC-FID parameters used in the method development were based on the boiling
point of the drug. The injection port and detector temperature were set to 170˚C and
250˚C, respectively. 
Manual splitless injection of approximately 2-µl sample was performed at an
inlet  temperature  of  170˚C.  The  detector  temperature  was  set  to  250˚C.  After
injection, the oven temperature was increased quickly from 80˚C to 180˚C at a rate of
100˚C per min for 5min. The initial carrier gas pressure was maintained at 29.8 Kpa
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for 3.5 minutes and pressure was increased at a rate of 20Kpa/min up to 120Kpa and
held constant for 4.50 min.
Synthetic air (flow rate of 100 ml/min), hydrogen (25 ml/min) were fed to the
FID. All the gases used in these studies were of Pharamcopoeial purity. 
LMT analysis was performed after derivatization, LMT is a polar molecule
and therefore, a polar solvent methanol was used as the diluent. The capillary column
coated with 5% diphenyl/ 95% dimethyl polysiloxane is a good choice for separation
of  this  analyte  since  they  elute  as  symmetrical  peaks  at  a  wide  range  of
concentrations.
10.5 ASSAY
Standard solutions of LMT in HPLC grade methanol, having final concentrations in
the range of 2-10 ng/mL were prepared. The drug solution and ECF were added in 1:1
ratio. The solution was heated at 700 C for 5 minutes. Solution was evaporated after
addition  of  pyridine  and  chloroform.  Upper  layer  was  collected,  redissolved  in
methanol. Two µl aliquot of each derivatized sample solution was injected on to the
column  and  the  chromatogram  (Fig.20) was  recorded.  Calibration  graph  was
constructed by plotting the mean peak area as a function of lamotrigine concentration
(Fig.21).
10.6 ANALYSIS OF TABLET DOSAGE FORM
Twenty tablets were weighed, powdered and their contents are mixed thoroughly. An
amount of powder equivalent to 10 mg  of a tablet was mixed with methanol and
shaken  for  20  min  at  a  frequency  of  approximately 3  cycle’s/s  in  sonicator.  The
solution was then filtered through 0.45 µm membrane filter. The drug solution and
ECF were added in 1:1 ratio. The solution was heated at 700 C for 5 minutes. Solution
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was evaporated after addition of pyridine and chloroform. Upper layer was collected,
redissolved in methanol and the chromatogram was shown in Fig. 22.
Fig.20. Chromatogram obtained from pure Lamotrigine (LMT) solution,
Methanol (A), ethyl chloroformate (B), lamotrigine (C)
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Fig.21. Calibration graph of LMT (2-10 ng/ml) on reaction with ECF
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Fig.22. Chromatogram obtained from formulation of Lamotrigine (LMT) tablet
solution, Methanol (A), ethyl chloroformate (B), lamotrigine (C).
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RESULTS AND DISCUSSION
PART A: UV-VISIBLE SPECTROPHOTOMETRY 
Table 1: Optical characters data of levetiracetam
S.N
O Parameter MBTH 2, 4-DNP BMR p-CA
Potassiu
m
ferricya
nide
1.
λmax(nm) 634 nm 455 nm 461 nm 440 nm 750 nm
2. Beers law limits 
(µg/ml)
20-100 30-130 50-350 50-350 100-400
3.
Molar 
absorptivit
y(liter 
/mol/cm)
1.6085×10-
3
1.38996×1
0-3 2.2806×10
-4 3.54016
0 ×10-4
3.18274
×10-4
4. Correlation
coefficient 
(R)
0.996 0.995 0.999 0.998 0.997
5.
Sandell’s 
sensitivity 
(g/ml 
0.001 abs 
unit)
0.089 0.054 0.746 0.480 0.534
6. Regression
equation 
(Y)
Y=0.007x+
0.018
Y=0.007x+
0.010
Y=0.0017x+
0.0067
Y=0.00
21x+
0.0092
Y= 
0.0018x 
+0.0022
7. Slope, b 0.007 0.007 0.001 0.002 0.001
8. Intercept, c 0.018 0.010 0.006 0.009 0.002
9. µ Relative 
standard 
deviation
0.325 0.422 0.395 0.248 0.268
 Y= bC+a, where C is the concentration of levetiracetam in µg/ml and Y is the 
absorbance at the respective maximum absorbance
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Table 2: Optical characters data of lamotrigine
S.NO Parameter Gibb’s MBTH BMR
1.
λmax(nm) 403 nm 662 nm 461 nm
2.
Beers law limits (µg/ml) 50-350 25-350 50-350
3.
Molar
absorptivity(liter
/mol/cm)
7.324x10-4
6.043
×10-4
2.2806×10-4
4. Correlation coefficient
(R)
0.996 0.998 0.999
5. Sandell’s sensitivity
(%g/ml 0.001 abs unit)
0.349 0.423 0.746
6.
Regression equation (Y)
Y= 0.002x
+ 0.012
Y =
0.002x +
0.016
Y=0.0017x+0.006
7
7.
Slope, b 0.002 0.002 0.001
8.
Intercept, c 0.012 0.016 0.006
9. µ Relative standard
deviation
0.251 0.230 0.395
          Y= bC+a, where C is the concentration of lamotrigine in µg/ml and Y is the 
absorbance at the respective maximum absorbance
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Table 3: Validation parameters of levetiracetam 
S.N
O
Parameters MBTH
2, 4-
DNP
BMR p-CA
Potassium
ferricyanid
e
1. Limit of detection
(%g/ml)
0.69 0.88 2.64 1.60 1.89
2.
Limit of
quantification(µg/ml
)
2.07 2.67 1.73 4.99 5.73
3.
Intraday RSD % 0.422 0.325 0.395 0.248 0.268
4.
Interday RSD % 0.653 0.587 0.413 0.453 0.387
5.
SEM 0.0017 0.0013 0.0055 0.0042 0.0042
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Table 4: Validation parameters of lamotrigine 
S.NO Parameters Gibb’s MBTH BMR
1.
Limit of detection
(µg/ml)
0.30 0.20 2.64
2.
Limit of
quantification(µg/ml
)
0.83 0.62 1.73
3. Intraday RSD % 0.25 0.23 0.30
4. Interday RSD % 0.478 0.534 0.435
5. SEM 0.0044 0.0012 0.0060
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Table 5: Recovery of levetiracetam in pharmaceutical formulations 
Formulati
on
Method Level
of %
Recov
ery
Sam
ple
LEV
(µg/
ml)
Standar
d
LEV(µg/
ml)
Avg.
amount
from
calibrat
ion
graph
Avg. %
Recove
ry*
%
R.S.
D
Levetirace
tam
MBTH
reagent
80% 20
24  43.50  99.40   0.2
1
100% 20 30 49.91 99.60 0.21
120% 20 36 55.93 99.77 0.14
2,4 DNP
reagent
80% 30 32 61.95 99.84 0.11
100% 30 40 69.95 99.84 0.10
120% 30 48 77.95 99.61 0.26
BM reagent
80% 50 80 129.91 99.77 0.13
100% 50 100 149.82 99.64 0.29
120% 50 120 169.79 99.58 0.28
p-CA
80% 50 80 129.95 99.85 0.15
100% 50 100 149.94 99.94 0.12
120%
50 120 169.89         
99.81
0.13
Pot.ferricya
nide
80%
100 120  219.80  99.80   0.1
5
100%
100 150 249.84         
99.84
0.14
120%
100 180  279.84  99.84   0.1
0
* Average of three determinations
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Table 6: Recovery of lamotrigine in pharmaceutical formulations 
Formulati
on
Metho
d
Level
of %
Recove
ry
Samp
le
LMT
(µg/m
l)
Standard
LMT(µg/
ml)
Avg.
amount
from
calibrati
on graph
Avg. %
Recover
y*
%
R.S.
D
 
Lamotrigi
ne
Gibb’
s
reage
nt
80% 50
80  129.84  99.68   0.2
1
100% 50 100 149.85 99.70 0.24
120% 50
120 169.86 99.73
0.20
MBT
H
reage
nt
80% 25 65 64.91 99.64 0.25
100% 25 75 74.92 99.68 0.16
120% 25
85 84.93 99.73
0.18
BM
reage
nt
80% 50 80 129.90 99.81 0.12
100% 50 100 149.91 99.83 0.11
120% 50
120 169.88 99.76
0.12
* Average of three determinations
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Table  7:  Validation  report  for  Gas  chromatography  for  determination  of
levetiracetam and lamotrigine
S.NO Parameters Levetiracetam Lamotrigine
1. Linearity(ng/ml) 2-10 2-10
2. LOD (ng/ml) 0.016 0.011
3. LOQ (ng/ml) 0.051 0.035
4. Intraday RSD % 0.12 0.17
5. Interday RSD % 0.13 0.25
6. Relative retention
time
0.991 0.990
          Table 8: Recovery values of levetiracetam and lamotrigine by GC-FID 
method in pharmaceutical preparations
Formulation Level of Sample Standar Avg. Avg. % %
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%
Recover
y
(µg/ml) d
(µg/ml)
amount
from
calibration
graph
Recovery* R.S.D
Levetiraceta
m
 
80% 2 3.2  5.19  99.96  0.017
100% 2 4.0 5.99 99.91 0.045
120% 2
6.8 6.79 99.91
0.053
Lamotrigine
80% 2 3.2 5.19 99.95 0.036
100% 2 4.0 5.98 99.92 0.040
120% 2 6.8 6.80 100.12 0.055
              * Average of three determinations
DISCUSSION
PART A: UV-VISIBLE SPECTROPHOTOMETRY
The  optical  characteristics  such  as  absorption  maxima,  Beer’s  law  limits,
molar  absorptivity,  Sandell’s  sensitivity,  %  Relative  standard  deviation  and  the
regression analysis using the method of  least  squares was made for the slope (b),
intercept (c) and correlation (r) obtained from different concentrations and results are
summarised for  Levetiracetam and Lamotrigine are presented in Table 1 and 2. The
validation parameters such as limit of detection, limit of quantification, intraday and
interday relative standard deviation and standard error mean values for Levetiracetam
and Lamotrigine were summarised in  Table 3 and 4.  The results  showed that  the
methods have reasonable precision. 
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 The results obtained with proposed methods confirm the suitability of these
methods for pharmaceutical dosage forms. The other active ingredients and excipients
usually present in the pharmaceutical dosage forms did not interfere in the estimation
when some commercial dosage forms were analysed by these methods. The accuracy
of the methods is confirmed by the recovery studies, by adding known amount of the
pure drug to the formulation already analysed by this method and the analytical data
presented in Table 5 and 6.
In  all  the above methods,  the optimum concentration for  the estimation of
levetiracetam and lamotrigine was established by varying one parameter at a time and
keeping the other fixed and observing the effect of product on the absorbance of the
colored species and incorporate in the procedures. The optimum concentration for the
estimation  of  levetiracetam  and  lamotrigine  was  established  by  varying  drug
concentration  by  keeping  the  reagent  concentration  fixed.  After  establishing  the
optimum  concentration  for  the  drug  the  reagent  concentration  was  varied  above
ranges of drug and reagents concentration were chosen because the colored species
formed gave better absorbance and obeys Beer’s law satisfactorily.
The methods reported here are found to be simple, sensitive, accurate, precise
and economical and can be used in the determination of levetiracetam and lamotrigine
from pharmaceutical dosage forms in a routine manner.
PART B: GAS CHROMATOGRAPHY METHODS
The development of analytical method for the determination of drugs by GC
has received considerable attention in recent  years  because of  their  importance  in
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quality control of drugs and drug products. The objective of this study was to develop
a rapid and sensitive GC method for the analysis of levetiracetam and lamotrigine in
bulk and its formulation using the most commonly employed Rtx-5 capillary column
with FID detection.
 The  run  time  was  set  at  11.82  min  and  levetiracetam  appeared  on  the
chromatogram at  7.79  min  and  lamotrigine  at  7.96  min.  When  the  samples  were
injected  six  times,  the  retention  times  of  the  drugs  were  same.  The  validated
parameters  such  as  linearity,  LOD,  LOQ,  intra  and  inter  day  R.S.D  and  relative
retention time are summarized in Table 7. The peak areas of drugs were reproducible
as indicated by low coefficient of variance. When the concentration of levetiracetam
and lamotrigine and its respective peak areas were subjected to regression analysis by
least squares method, a high correlation coefficient were observed (r2=0.997 for both
drugs) in the range of 2-10 ng/ml. The regression equation was used to estimate the
amount  of  levetiracetam  and  lamotrigine  in  formulations  or  in  validation  study
(precision and accuracy).
The  proposed  GC  methods  were  also  validated  for  intra  and  inter  day
variations.  Thus,  the  results  showed  that  the  proposed  GC  method  is  highly
reproducible. When a known concentration of drug solution was added to preanalyzed
samples of commercial dosage forms of levetiracetam and lamotrigine, there was high
recovery of these drugs table indicating that the proposed method is highly accurate
and the values are presented in Table 8.
The GC method developed in the present  study has  been used to quantify
levetiracetam and lamotrigine in tablet dosage form. No interfering peaks were found
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in the chromatogram indicating that the excipients used in the formulation did not
interfere with the estimation of the drug by the proposed GC method.
SUMMARY
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Several  drugs  are  available  in  the  form of  pharmaceutical  formulations  to
control  diseases.  Methods  of  assay  for  controlling  the  concentration  of  these
chemicals  in  the  medicine  and  in  the  living  body  are  necessary.  Pharmaceutical
analysis  occupies  a  pivotal  role  in  statutory  certification  of  drugs  and  their
formulations either by the industry or by the regulatory authorities. The complexity of
the  problem  encountered  in  pharmaceutical  analysis  coupled  with  importance  of
achieving the selectivity, speed, cost, simplicity, precision and accuracy results in new
methods of analysis being quickly adopted by pharmaceutical industry.
The ever increasing use of pharmacodynamics and chemotherapeutic agents in
pharmaceutical  preparations  makes  their  determinations  a  matter  of  foremost
importance. In some cases, no precise analytical methods are reported and quite often
the reported methods need improvement or changes keeping in view of the advances.
Among several instrumental techniques (HPLC, GC, fluorimetry, NMR, mass
spectroscopy covering  IR,  UV and  visible  regions)  available  for  assay  of  drugs,
visible spectrophotometric methods depend only on the nature of chemical reaction
utilized for color development and not on sophistication of the equipment. GC method
is highly selective and sensitive compared to spectroscopic or other chromatographic
methods. GC method is also cost effective as expensive solvents are not required and
it is  a  versatile  tool  for  qualitative  and  quantitative  analysis  of  drugs  and
pharmaceuticals.
Due  to  the  importance  of  analysis,  present  analytical  method  has  been
developed for some of the widely used drugs such as levetiracetam and lamotrigine.
Hence we planned to develop both GC and spectrophotometric methods.
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There is a wide scope for the development of new analytical methods for the
assay of the levetiracetam and lamotrigine. Visible spectrometry (part A) and GC (part
B) techniques have been used as a tool in the present thesis work. The above two tools
have been used for the development of new analytical methods for the assay of drugs
mentioned by exploiting their physical and chemical properties (dependent on basic
moieties and functional groups present in each drug).
CONCLUSION
PART A: UV-VISIBLE SPECTROPHOTOMETRY
Levetiracetam
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Levetiracetam is a novel antiepileptic drug which is structurally dissimilar to
other antiepileptic drugs.  It  is chemically (αS)-α-ethyl-2-oxo-1-yrrolidineacetamide.
This is a structural analog of piracetam, which binds to a synaptic vesicle protein
SV2A. This is believed to impede nerve conduction across synapses.
The therapeutic importance of this compound justifies research to establish
analytical method for its determination in bulk and pharmaceutical formulations.    
In  previous  reports  high  performance  liquid  chromatographic  methods  and
only few spectrophotometric methods were developed. Need for the development of
simple spectrophotometric methods for its assay is highly demanding. In the view of
above fact, some simple analytical methods were planned to develop with sensitivity,
accuracy, precision and economical. Since levetiracteam is soluble in distilled water
and methanol,  a  number of  spectrophotometric  methods can be developed for  the
quantitative estimation of drug in bulk and pharmaceutical formulations.
In part A, set of five simple, sensitive, accurate and precise spectrophotometric
methods (methods 1 to 5) has been developed for the purpose. The results expressed
in Table  1-6  for  spectrophotometric  methods.  The  striking  advantage  of  all  the
presently developed methods is that they are economical.
The methods are validated in terms of sensitivity, accuracy and precision.
A. Comparative Sensitivity:
     2 > 1 > 4 > 5 > 3
B. Comparative accuracy:
                4 > 5 > 2 > 3 > 1 
C. Comparative precision:
    4 > 5 > 1 > 3 > 2 
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These methods can be used for the routine determination of levetiracteam in
bulk drugs and in pharmaceutical formulations.
In part B, in present investigation, we have developed sensitive, precise and
accurate gas chromatography method (method 9) for the quantitative estimation of
levetiracteam in its bulk and pharmaceutical formulations. The results expressed in
Table 7 and 8 for gas chromatography is promising. The advantage of the developed
GC methods is that it is sensitive and precise. As only small quantity of solvents is
used the method is proved to be economical. 
This method can be used for the routine determination of levetiracetam in bulk
drugs and pharmaceutical formulations.
Lamotrigine
Lamotrigine [6-(2, 3-Dichlorophenyl)-1, 2, 4-triazine-3, 5-diamine] is a broad
spectrum antiepileptic  drug,  chemically  different  from other  anti-convulsants.  The
mechanism  of  action  of  lamotrigine  is  inhibition  of  the  release  of  excitatory
neurotransmitters (aspartate and glutamate) and also involvement of the blocking of
voltage dependent sodium channels. Lamotrigine is effective for treatment of partial
and generalized tonic, clonic seizures as a single drug or as an adjuvant with other anti
epileptic drugs.
A HPLC method has been reported in the British Pharmacopoeia. Need for the
development of simple spectrophotometric methods for its assay is highly demanding.
Here  three  simple  sensitive  precise  and  accurate  UV-visible
spectrophotometric methods have been established for the quantitative estimation of
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lamotrigine  in  its  bulk  and  pharmaceutical  formulations.  The  results  are  given  in
Table 2, 4, and 6. 
The methods are validated in terms of sensitivity, accuracy and precision.
A. Comparative Sensitivity:
         3> 1 > 2
B. Comparative accuracy:
                    3> 1 > 2  
C. Comparative precision:
                     2 >1 > 3
These methods can be used for the routine determination of lamotrigine in
bulk drugs and in pharmaceutical formulations.
In part B, in present investigation, we have developed sensitive, precise and
accurate Gas chromatography method (method 10) for the quantitative estimation of
lamotrigine  in  its  bulk  and  pharmaceutical  formulations.  The results  expressed  in
Table 7 and 8 for gas chromatography is promising. The advantage of this developed
GC method is that it is sensitive and precise.
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